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METHODS FOR TREATING CONGESTIVE 
HEART FAILURE 
This application is a continuation of application Ser. No. 
12/655,361 filed Dec. 29, 2009, now U.S. Pat. No. 8,076,283, 
which is a divisional of application Ser. No. 10/646,268 filed 
Aug. 22, 2003, now U.S. Pat. No. 7,662,772, which is a 
divisional of application Ser. No. 09/298,121 filed Apr. 23, 
1999, now U.S. Pat. No. 6,635,249, the contents of which are 
each hereby incorporated by reference in their entireties. 
STATEMENT AS TO FEDERALLY SPONSORED 
RESEARCH 
This work was supported in part by NIH Grants HL-38189, 
HL-36141, and a NASA award. The government has certain 
rights in the invention. 
FIELD OF THE INVENTION 
The field of the invention is treatment and prevention of 
congestive heart failure. 
BACKGROUND OF THE INVENTION 
Congestive heart failure, one of the leading causes of death 
in industrialized nations, results from an increased workload 
on the heart and a progressive decrease in its pumping ability. 
Initially, the increased workload that results from high blood 
pressure or loss of contractile tissue induces compensatory 
cardiomyocyte hypertrophy and thickening of the left ven-
tricular wall, thereby enhancing contractility and maintaining 
cardiac function. However, over time, the left ventricular 
chamber dilates, systolic pump function deteriorates, cardi-
omyocytes undergo apoptotic cell death, and myocardial 
function progressively deteriorates. 
Factors that underlie congestive heart failure include high 
blood pressure, ischemic heart disease, exposure to car-
diotoxic compounds such as the anthracycline antibiotics, 
and genetic defects known to increase the risk of heart failure. 
Neuregulins (NRGs) and NRG receptors comprise a 
growth factor-receptor tyrosine kinase system for cell-cell 
signalling that is involved in organogenesis in nerve, muscle, 
epithelia, and other tissues (Lemke, Mol. Cell. Neurosci. 7: 
247-262, 1996 and Burden et al., Neuron 18: 847-855, 1997). 
The NRG family consists of three genes that encode numer-
ous ligands containing epidermal growth factor (EGF)-like, 
immunoglobulin (Ig), and other recognizable domains. At 
least 20 (perhaps 50 or more) secreted and membrane-at-
tached isoforms may function as ligands in this signalling 
system. The receptors for NRG ligands are all members of the 
EGF receptor (EGFR) family, and include EGFR (or ErbB 1), 
ErbB2, ErbB3, and ErbB4, also known as HERI through 
HER4, respectively, in humans (Meyer et al., Development 
124: 3575-3586, 1997; Orr-Urtreger et al., Proc. Natl. Acad. 
Sci. USA 90: 1867-71, 1993; Marchionni et al., Nature 362: 
312-8, 1993; Chen et al., J. Comp. Neurol. 349: 389-400, 
1994; Corfas et al., Neuron 14: 103-115, 1995; Meyer et al., 
Proc. Natl. Acad. Sci. USA 91:1064-1068,1994; and Pinkas-
Kramarski et al., Oncogene 15: 2803-2815, 1997). 
The three NRG genes, Nrg-1, Nrg-2, and Nrg-3, map to 
distinct chromosomal loci (Pinkas-Kramarski et al., Proc. 
Natl. Acad. Sci. USA 91: 9387-91, 1994; Carraway et al., 
Nature 387: 512-516, 1997; Chang et al., Nature 387: 509-
511, 1997; and Zhang et al., Proc. Natl. Acad. Sci. USA 94: 
9562-9567, 1997), and collectively encode a diverse array of 
NRG proteins. The most thoroughly studied to date are the 
2 
gene products of Nrg-1, which comprise a group of approxi-
mately 15 distinct structurally-related isoforms (Lemke, Mol. 
Cell. Neurosci. 7: 247-262, 1996 and Peles and Yarden, 
BioEssays 15: 815-824, 1993). The first-identified isoforms 
5 ofNRG-1 included Neu Differentiation Factor (NDF; Peles et 
al., Cell 69, 205-216, 1992 and Wen et al., Cell 69, 559-572, 
1992), Heregulin (HRG; Holmes et al., Science 256: 1205-
1210, 1992), Acetylcholine Receptor Inducing Activity 
10 
(ARIA; Falls et al., Cell 72: 801-815, 1993), and the glial 
growth factors GGF1, GGF2, and GGF3 (Marchionni et al. 
Nature 362: 312-8, 1993). 
The Nrg-2 gene was identified by homology cloning 
(Chang et al., Nature 387:509-512, 1997; Carraway et al., 
15 Nature 387:512-516, 1997; and Higashiyama et al., J. Bio-
chem, 122: 675-680, 1997) and through genomic approaches 
(Busfield et al., Mol. Cell. Biol. 17:4007-4014,1997). NRG-2 
cDNAs are also known as Neural- and Thymus-DerivedActi-
vator of ErbB Kinases (NTAK; Genbank Accession No. 
20 A13005060), Divergent of Neuregulin (Don-1), and Cerebel-
lum-Derived Growth Factor (CDGF; PCT application WO 
97/09425). Experimental evidence shows that cells express-
ing ErbB4 or the ErbB2/ErbB4 combination are likely to 
show a particularly robust response to NRG-2 (Pinkas-Kra- 
25 marski et al., Mol. Cell. Biol. 18: 6090-6101, 1998). The 
Nrg-3 gene product (Zhang et al., supra) is also known to bind 
and activate ErbB4 receptors (Hijazi et al., Int. J. Oncol. 
13:1061-1067, 1998). 
An EGF-like domain is present at the core of all forms of 
30 NRGs, and is required for binding and activating ErbB recep-
tors. Deduced amino acid sequences of the EGF-like domains 
encoded in the three genes are approximately 30-40% iden-
tical (pairwise comparisons). Further, there appear to be at 
least two sub-forms of EGF-like domains in NRG-1 and 
35 NRG-2, which may confer different bioactivities and tissue-
specific potencies. 
Cellular responses to NRGs are mediated through the NRG 
receptor tyrosine kinases EGFR, ErbB2, ErbB3, and ErbB4 
of the epideimal growth factor receptor family. High-affinity 
40 binding of all NRGs is mediated principally via either ErbB3 
or ErbB4. Binding of NRG ligands leads to dimerization with 
other ErbB subunits and transactivation by phosphorylation 
on specific tyrosine residues. In certain experimental settings, 
nearly all combinations of ErbB receptors appear to be 
45 capable of forming dimers in response to the binding of 
NRG-1 isoforms, However, it appears that ErbB2 is a pre-
ferred dimerization partner that may play an important role in 
stabilizing the ligand-receptor complex. Recent evidence has 
shown that expression of NRG-1, ErbB2, and ErbB4 is nec- 
50 essary for trabeculation of the ventricular myocardium during 
mouse development. 
In view of the high prevalence of congestive heart failure in 
the general population, it would be highly beneficial to pre-
vent or minimize progression of this diseaseby inhibiting loss 
55 of cardiac function, and ideally, by improving cardiac func-
tion for those who have or are at risk for congestive heart 
failure. 
SUMMARY OF THE INVENTION 
60 
We have found that neuregulins stimulate compensatory 
hypertrophic growth and inhibit apoptosis of myocardiocytes 
subjected to physiological stress. Our observations indicate 
that neuregulin treatment will be useful for preventing, mini- 
65 mizing, or reversing congestive heart disease resulting from 
underlying factors such as hypertension, ischemic heart dis-
ease, and cardiotoxicity. 
US 8,394,761 B2 
3 
	
4 
The invention provides a method for treating or preventing 	 namic monitoring, magnetic resonance angiography, and 
congestive heart failure in a mammal. The method involves 	 exercise treadmill testing coupled with oxygen uptake stud- 
administering a polypeptide that contains an epidermal 
	
ies. 
growth factor-like (EGF-like) domain to the mammal, 	 By "ischemic heart disease" is meant any disorder result- 
wherein the EGF-like domain is encoded by a neuregulin 5 ing from an imbalance between the myocardial need for oxy- 
gene, and wherein administration of the polypeptide is in an 	 gen and the adequacy of the oxygen supply. Most cases of 
amount effective to treat or prevent heart failure in the mam- 	 ischemic heart disease result from narrowing of the coronary 
mal. 	 arteries, as occurs in atherosclerosis or other vascular disor- 
In various preferred embodiments of the invention, the 	 ders. 
neuregulin gene may be the NRG-1 gene, the NRG-2 gene, or 10 By "myocardial infarction" is meant a process by which 
the NRG-3 gene. Furthermore, the polypeptide may be 	 ischemic disease results in a region of the myocardium being 
encoded by any of these three neuregulin genes. Still further, 	 replaced by scar tissue. 
the polypeptide used in the method may be recombinant 	 By "cardiotoxic" is meant a compound that decreases heart 
human GGF2. 	 function by directing or indirectly impairing or killing cardi- 
In another preferred embodiment of the invention, the 15 omyocytes. 
mammal is a human. 	 By "hypertension" is meant blood pressure that is consid- 
In other embodiments of the invention, the congestive heart 	 ered by a medical professional (e.g., a physician or a nurse) to 
failure may result from hypertension, ischemic heart disease, 	 be higher than normal and to carry an increased risk for 
exposure to a cardiotoxic compound (e.g., cocaine, alcohol, 	 developing congestive heart failure. 
an anti-ErbB2 antibody or anti-HER2 antibody, such as HER-  20 	 By "treating" is meant that administration of a neuregulin 
CEPTINO, or an anthracycline antibiotic, such as doxorubi- 	 or neuregulin-like polypeptide slows or inhibits the progres- 
cin or daunomycin), myocarditis, thyroid disease, viral infec- 	 sion of congestive heart failure during the treatment, relative 
tion, gingivitis, drug abuse; alcohol abuse, periocarditis, 	 to the disease progression that would occur in the absence of 
atherosclerosis, vascular disease, hypertrophic cardiomyopa- 	 treatment, in a statistically significant manner. Well known 
thy, acute myocardial infarction or previous myocardial inf-  25 indicia such as left ventricular ejection fraction, exercise per- 
arction, left ventricular systolic dysfunction, coronary bypass 	 formance, and other clinical tests as enumerated above, as 
surgery, starvation, an eating disorder, or a genetic defect. 	 well as survival rates and hospitalization rates may be used to 
In another embodiment of the invention, an anti-ErB2 or 	 assess disease progression. Whether or not a treatment slows 
anti4HER2 antibody, such as HERCEPTINO, is adminis- 	 or inhibits disease progression in a statistically significant 
tered to the mammal either before, during, or after anthracy-  30 manner may be determined by methods that are well known in 
cline administration. 	 the art (see, e.g., SOLVD Investigators, N. Engl. J. Med. 
In other embodiments of the invention, the polypeptide 	 327:685-691, 1992 and Cohn et al., N. Engl. J. Med. 339: 
containing an EGF-like domain encodedby a neuregulin gene 	 1810-4816, 1998). 
is administered before, during, or after exposure to a car- 	 By "preventing" is meant minimizing or partially or com- 
diotoxic compound. In yet other embodiments, the polypep-  35 pletely inhibiting the development of congestive heart failure 
tide containing the EGF-like domain is administered during 	 in a mammal at risk for developing congestive heart failure 
two, or all three, of these periods. 	 (as defined in "Consensus recommendations for the manage- 
In still other embodiments of the invention, the polypeptide 	 ment of chronic heart failure."Am.J.. Cardiol., 83(2A): 1A38- 
is administered either prior to or after the diagnosis of con- 	 A, 1999). Determination of whether congestive heart failure 
gestive heart failure in the mammal. 	 40 is minimized or prevented by administration of a neurgulin or 
In yet another embodiment of the invention, the polypep- 	 neuregulin-like polypeptide is made by known methods, such 
tide is administered to a mammal that has undergone com- 	 as those described in SOLVD Investigators, supra, and Cohn 
pensatory cardiac hypertrophy. 	 et al., supra. 
In other preferred embodiments of the invention, adminis- 	 By "at risk for congestive heart failure" is meant an indi- 
tration of the polypeptide maintains left ventricular hypertro-  45 vidual who smokes, is obese (i.e., 20% or more over their 
phy, prevents progression of myocardial thinning, or inhibits 	 ideal weight), has been or will be exposed to a cardiotoxic 
cardiomyocyte apoptosis. 	 compound (such as an anthracycline antibiotic), or has (or 
In yet another embodiment of the invention, the polypep- 	 had) high blood pressure, ischemic heart disease, a myocar- 
tide may be administered by administering an expression 	 dial infarct, a genetic defect known to increase the risk of 
vector encoding the polypeptide to the mammal. 	 5o heart failure, a family history of heart failure, myocardial 
By "congestive heart failure" is meant impaired cardiac 	 hypertrophy, hypertrophic cardiomyopathy, left ventricular 
function that renders the heart unable to maintain the normal 	 systolic dysfunction, coronary bypass surgery, vascular dis- 
blood output at rest or with exercise, or to maintain a normal 	 ease, atherosclerosis, alcoholism, periocarditis, a viral infec- 
cardiac output in the setting of normal cardiac filling pressure. 	 tion, gingivitis, or an eating disorder (e.g., anorexia nervosa 
A left ventricular ejection fraction of about 40% or less is 55 or bulimia), or is an alcoholic or cocaine addict. 
indicative of congestive heart failure (by way of comparison, 	 By "decreasing progression of myocardial thinning" is 
an ejection fraction of about 60% percent is normal). Patients 	 meant maintaining hypertrophy of ventricular cardiomyo- 
in congestive heart failure display well-known clinical symp- 	 cytes such that the thickness of the ventricular wall is main- 
toms and signs, such as tachypnea, pleural effusions, fatigue 	 tained or increased. 
at rest or with exercise, contractile dysfunction, and edema. 60 	 By "inhibits myocardial apoptosis" is meant that neuregu- 
Congestive heart failure is readily diagnosed by well known 	 lin treatment inhibits death of cardiomyocytes by at least 
methods (see, e.g., "Consensus recommendations for the 	 10%, more preferably by at least 15%, still more preferably 
management of chronic heart failure." Am. J. Cardiol., 	 by at least 25%, even more preferably by at least 50%, yet 
83(2A):1A-38-A, 1999). 	 more preferably by at least 75%, and most preferably by at 
Relative severity and disease progression are assessed 65 least 90%, compared to untreated cardiomyocytes. 
using well known methods, such as physical examination, 	 By "neuregulin" or "NRG" is meant a polypeptide that is 
echocardiography, radionuclide imaging, invasive hemody- 	 encoded by an NRG-1, NRG-2, or NRG-3 gene or nucleic 
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acid (e.g., a cDNA), and binds to and activates ErbB2, ErbB3, 
or ErbB4 receptors, or combinations thereof. 
By "neuregulin-1," "NRG-1," "heregulin," "GGF2," or 
11p185erbB2 ligand" is meant a polypeptide that binds to the 
ErbB2 receptor and is encoded by the  I85erbB2 ligand gene 
described in U.S. Pat. No. 5,530,109; U.S. Pat. No. 5,716, 
930; and U.S. Ser. No. 08/461,097. 
By "neuregulin-like polypeptide" is meant a polypeptide 
that possesses an EGF-like domain encoded by a neuregulin 
gene, and binds to and activates ErbB-2, ErbB-3, ErbB-4, or 
a combination thereof. 
By "epidermal growth factor-like domain" or "EGF-like 
domain" is meant a polypeptide motif encodedby the NRG-1, 
NRG-2, or NRG-3 gene that binds to and activates ErbB2, 
ErbB3, ErbB4, or combinations thereof, andbears a structural 
similarity to the EGF receptor-binding domain as disclosed in 
Holmes et al., Science 256:1205-1210, 1992; U.S. Pat. No. 
5,530,109; U.S. Pat. No. 5,716,930; U.S. Ser. No. 08/461, 
097; Hijazi et al., Int. J. Oncol. 13:1061-1067,1998; Chang et 
al., Nature 387:509-512, 1997; Carraway et al., Nature 387: 
512-516, 1997; Higashiyama et al., J. Biochem. 122: 675-
680, 1997; and WO 97/09425). 
By "anti-ErbB2 antibody" or "anti-HER2 antibody" is 
meant an antibody that specifically binds to the extracellular 
domain of the ErbB2 (also known as HER2 in humans) recep-
tor and prevents the ErbB2 (HER2)-dependent signal trans-
duction initiated by neuregulin binding. 
By "transformed cell" is meant a cell (or a descendent of a 
cell) into which a DNA molecule encoding a neuregulin or 
polypeptide having a neuregulin EGF-like domain has been 
introduced, by means of recombinant DNA techniques or 
known gene therapy techniques. 
By "promoter" is meant a minimal sequence sufficient to 
direct transcription. Also included in the invention are those 
promoter elements which are sufficient to render promoter-
dependent gene expression controllable for cell type orphysi-
ological status (e.g., hypoxic versus normoxic conditions), or 
inducible by external signals or agents; such elements may be 
located in the 5' or 3' or internal regions of the native gene. 
By "operably linked" is meant that a nucleic acid encoding 
a polypeptide (e.g., a cDNA) and one or more regulatory 
sequences are connected in such a way as to permit gene 
expression when the appropriate molecules (e.g., transcrip-
tional activator proteins) are bound to the regulatory 
sequences. 
By "expression vector" is meant a genetically engineered 
plasmid or virus, derived from, for example, a bacteriophage, 
adenovirus, retrovirus, poxvirus, herpesvirus, or artificial 
chromosome, that is used to transfer a polypeptide (e.g., a 
neuregulin) coding sequence, operably linked to a promoter, 
into a host cell, such that the encoded peptide or polypeptide 
is expressed within the host cell. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. lA is a representation of a semiquantitative RT-PCR 
analysis showing expression of neuregulin receptors during 
cardiac development and in adult rat cardiomyocytes. 
FIG. 1B is a representation of an assay showing tyrosine 
phosphorylation of the ErbB4 receptor in cardiomyocytes 
treated with recombinant human glial growth factor 2 
(rhGGF2). 
FIGS. 2A and 2B are representations of photomicrographs 
showing staining of neonatal rat ventricular myocytes for 
myosin heavy chain (FIG. 2A) and BrdU-positive nuclei 
(FIG. 2B). 
6 
FIG. 2C is a graph showing that rhGGF2 stimulates DNA 
synthesis (indicated by % BrdU-positive myocytes) in neo-
natal rat ventricular myocytes. 
FIGS. 3A and 3B are graphs showing that rhGGF2 stimu-
5 lates DNA synthesis (indicated by % relative 3H-thymidine 
uptake) in neonatal rat ventricular myocytes. 
FIG. 4 is a graph showing that ErbB2 and ErbB4 mediate 
the effects of GGF2 on relative 3H-thymidine uptake in neo-
natal rat ventricular myocytes. 
10 	 FIG. 5 is a graph showing that GGF2 promotes survival in 
primary cultures of neonatal rat ventricular myocytes. 
FIGS. 6A-6C and 6E-6G are representations of photomi-
crographs showing that GGF2 diminishes apoptotic cell 
death in primary cultures of neonatal rat ventricular myo- 
15 cytes. 
FIG. 6D is a graph showing that rhGGF2 diminishes apo-
ptotic cell death in primary cultures of neonatal rat ventricular 
myocytes (indicated by a decrease in the percentage of 
TUNEL-positive myocytes). 
20 FIG. 6H is a graph showing that rhGGF2 diminishes apo-
ptotic cell death in primary cultures of neonatal rat ventricular 
myocytes (determined by flow cytometry analysis of the sub-
GI fraction following propidium iodide staining of rhGGF2-
treated cells). 
25 FIGS. 7A and 7B are graphs showing that rhGGF2 
increases survival and decreases apoptotic cell death in pri-
mary cultures of adult rat ventricular myocytes. 
FIGS. 8A and 8B are representations of photomicrographs 
showing that GGF2 induces hypertrophic growth of neonatal 
3o rat ventricular myocytes. 
FIG. 8C is a representation of a Northern blot, showing that 
prepro-atrial natriuretic factor (prepro-ANF), a marker of 
ventricular hypo trophy, and a-skeletal actin are up-regulated 
in neonatal rat ventricular myocytes treated with GGF2. 
35 FIG. 8D is a graph showing that GGF2 stimulates protein 
synthesis (indicated by relative 3 H-leucine uptake) in neona-
tal rat ventricular myocytes. 
FIGS. 9A-9C are photomicrographs showing that GGF2 
induces hypertrophic growth in primary cultures of adult rat 
40 ventricular myocytes. 
FIG. 9D is a representation of Northern blots showing that 
prepro-ANF and a-skeletal actin are up-regulated in adult rat 
ventricular myocytes treated with GGF2. 
FIG. 9E is a graph showing that GGF2 stimulates protein 
45 synthesis (indicated by relative 3H-leticine uptake) in adult 
rat ventricular myocytes. 
FIGS. 10A and 10B are representations of ribonuclease 
protection assays showing expression levels of ErbB2 (FIG. 
10A), ErbB4 (FIG. 10B), and R -actin in the left ventricles of 
50 control and aortic stenosis rat hearts. 
FIG. 11 is a representation of a Northern blot showing 
expression of ANF and glyceraldehyde phosphate dehydro-
genase (GAPDH, a housekeeping gene) in myocytes from left 
ventricles of control and aortic stenosis rat hearts. 
55 	 FIGS. 12A and 12B are representations of ribonuclease 
protection assays showing expression levels of ErbB2 (FIG. 
12A), ErbB4 (FIG. 12B), and R -actin in myocytes from the 
left ventricles of control and aortic stenosis rat hearts. 
FIGS. 13A and 13B are representations of a Western blot 
60 showing expression levels of ErbB2 in 6-week (FIG. 13A) 
and 22-week (FIG. 13B) aortic stenosis and control rathearts. 
FIGS. 13C and 13D are representations of a Western blot 
showing expression levels of ErbB2 in 6-week (FIG. 13C) 
and 22-week (FIG. 13D) aortic stenosis and control rat hearts. 
65 FIG. 14 is a graph showing that rat cardiomyocyte cultures 
pre-treated with IGF-1 or NRG-1 are less susceptible to 
daunorubicin-induced apoptosis. 
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FIG. 15A is a representation of a phosphorylation assay 	 cardioproctive neuregulin treatment prior to the development 
showing that IGF- and NRG-1-stimulated pho sphorylation of 	 of compensatory hypertrophy. 
Akt is inhibited by the PI-3 kinase inhibitor wortmannin. 	 Neuregulin administration to cancer patients prior to and 
FIG. 15B is a graph showing that IGF-1 and NRG-1 inhi- 	 during anthracycline chemotherapy or anthracyclinelanti- 
bition of caspase 3 activation in cells exposed to daunorubicin 5 ErbB2 (anti-HER2) antibody (e.g., HERCEPTINO) combi- 
is PI-3 kinase-dependent. 	 nation therapy may prevent the patients' cardiomyocytes 
from undergoing apoptosis, thereby preserving cardiac func- 
DETAILED DESCRIPTION OF THE INVENTION 	 tion. Patients who have already suffered cardiomyocyte loss 
may also derive benefit from neuregulin treatment, because 
We have found that neuregulins promote survival and io the remaining myocardial tissue will respond to neuregulin 
hypertrophic growth of cultured cardiac myocytes through 	 exposure by displaying hypertrophic growth and increased 
activation of ErbB2 and ErbB4 receptors. 	 contractility. 
In addition, we have observed, in animals with experimen- 	 Therapy 
tally-induced intracardiac pressure overload, that cardiomyo- 	 Neuregulins and polypeptides containing EGF-like 
cyte ErbB2 and ErbB4 levels are normal during early com-  15 domains encoded by neuregulin genes may be administered 
pensatory hypertrophy and decrease during the transition to 	 to patients or experimental animals with a pharmaceutically- 
early heart failure. 	 acceptable diluent, carrier, or excipient, in unit dosage form. 
Together, our in vitro and in vivo findings show that neu- 	 Conventional pharmaceutical practice may be employed to 
regulins are involved in stimulating compensatory hyper- 	 provide suitable formulations or compositions to administer 
trophic growth in response to increased physiologic stress, as 20 such compositions to patients or experimental animals. 
well as inhibiting apoptosis of myocardial cells subjected to 	 Although intravenous administration is preferred, any appro- 
such stress. These observations indicate that neuregulin treat- 	 priate route of administration may be employed, for example, 
ment will be useful for preventing, minimizing, or reversing 	 parenteral, subcutaneous, intramuscular, intracranial, intraor- 
congestive heart disease. While not wishing to be bound by 	 bital, ophthalmic, intraventricular, intracapsular, intraspinal, 
theory, it is likely that neuregulin treatment will strengthen 25 intracisternal, intraperitoneal, intranasal, aerosol, oral, or 
the pumping ability of the heart by stimulating cardiomyo- 	 topical (e.g., by applying an adhesive patch carrying a formu- 
cyte hypertrophy, and will partially or completely inhibit 	 lation capable of crossing the dermis and entering the blood- 
further deterioration of the heart by suppressing cardiomyo- 	 stream) administration. Therapeutic formulations may be in 
cyte apoptosis. 	 the form of liquid solutions or suspensions; for oral adminis- 
Neuregulins 	 30 tration, formulations may be in the form of tablets or cap- 
Polypeptides encoded by the NRG-1, NRG-2, and NRG-3 	 sules; and for intranasal formulations, in the form of powders, 
genes possess EGF-like domains that allow them to bind to 	 nasal drops, or aerosols. Any of the above formulations may 
and activate ErbB receptors. Holmes et al. (Science 256: 	 be a sustained-release formulation. 
1205-1210,1992) has shown that the EGF-like domain alone 	 Methods well known in the art for making formulations are 
is sufficient to bind and activate the p185erbB2 receptor. 35 found in, for example, "Remington's Pharmaceutical Sci- 
Accordingly, any polypeptide product encoded by the NRG- 	 ences." Formulations for parenteral administration may, for 
1, NRG-2, or NRG-3 gene, or any neuregulin-like polypep- 	 example, contain excipients, sterile water, or saline, polyalky- 
tide, e.g., a polypeptide having an EGF-like domain encoded 
	
lene glycols such as polyethylene glycol, oils of vegetable 
by a neuregulin gene or cDNA (e.g., an EGF-like domain 	 origin, or hydrogenated napthalenes. Sustained-release, bio- 
containing the NRG-1 peptide subdomains C-C/D or C-C/D', 40 coinpatible, biodegradable lactide polymer, lactideiglycolide 
as described in U.S. Pat. No. 5,530,109, U.S. Pat. No. 5,716, 	 copolymer, or polyoxyethylene-polyoxypropylene copoly- 
930, and U.S. Ser. No. 08/461,097; or an EGF-like domain as 	 mers may be used to control the release of the compounds. 
disclosed in WO 97/09425) may be used in the methods of the 	 Other potentially useful parenteral delivery systems for 
invention to prevent or treat congestive heart failure. 	 administering molecules of the invention include ethylene- 
Risk Factors 	 45 vinyl acetate copolymer particles, osmotic pumps, implant- 
Risk factors that increase the likelihood of an individual's 	 able infusion systems, and liposomes. Formulations for inha- 
developing congestive heart failure are well known. These 	 lation may contain excipients, for example, lactose, or may be 
include, and are not limited to, smoking, obesity, high blood 	 aqueous solutions containing, for example, polyoxyethylene- 
pressure, ischemic heart disease, vascular disease, coronary 	 9-lauryl ether, glycocholate and deoxycholate, or may be oily 
bypass surgery, myocardial infarction, left ventricular sys-  50 solutions for administration in the form of nasal drops, or as 
tolic dysfunction, exposure to cardiotoxic compounds (alco- 	 a gel. 
hol, drugs such as cocaine, and anthracycline antibiotics such 
	
Gene Therapy 
as doxorubicin, and daunorubicin), viral infection, pericardi- 	 Neuregulins and neuregulin-like polypeptides containing 
tis, myocarditis, gingivitis, thyroid disease, genetic defects 	 neuregulin EGF-like domains may also be administered by 
known to increase the risk of heart failure (such as those 55 somatic gene therapy. Expression vectors forneuregulin gene 
described in Bachinski and Roberts, Cardiol. Clin. 16:603- 	 therapy (e.g., plasmids, artificial chromosomes, or viral vec- 
610, 1998; Sin et al., Circulation 8:1022-1026, 1999; and 	 tors, such as those derived from adenovirus, retrovirus, pox- 
Arbustini et al., Heart 80:548-558, 1998), starvation, eating 	 virus, or herpesvirus) carry a neuregulin-encoding (or neu- 
disorders such as anorexia and bulimia, family history of 	 reguhn-like polypeptide-encoding) DNA under the 
heart failure, and myocardial hypertrophy. 	 60 transcriptional regulation of an appropriate promoter. The 
Accordingly, neuregulins may be administered to prevent 	 promoter may be any non-tissue-specific promoter known in 
or decrease the rate of congestive heart disease progression in 	 the art (for example, an SV-40 or cytomegalovirus promoter). 
those identified as being at risk. For example, neuregulin 	 Alternatively, the promoter may be a tissue-specific pro- 
administration to a patient in early compensatory hypertro- 	 moter, such as a striated muscle-specific, an atrial or ventricu- 
phy may permit maintenance of the hypertrophic state and 65 lar cardiomyocyte-specific (e.g., as described in Franz et al., 
may prevent the progression to heart failure. In addition, 	 Cardiovasc. Res. 35:560-566, 1997), or an endothelial cell- 
those identified to be at risk, as defined above, may be given 	 specific promoter. The promoter may be an inducible pro- 
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moter, such as the ischemia-inducible promoter described in 	 followed by one change of medium to remove loosely 
Prentice et al. (Cardiovasc. Res. 35:567-574, 1997). The pro- 	 attached cells. The contamination ofARVM primary cultures 
moter may also be an endogenous neuregulin promoter. 	 by non-myocytes was determined by counting with a 
The expression vector may be administered as naked DNA 
	 haemocytometer and was typically less than 5%. All ARVM 
mixed with or conjugated to an agent to enhance the entry of 5 primary cultures were maintained in a defined medium 
the DNA into cells, e.g., a cationic lipid such as LipofectinTM 
	
termed "ACCITT" (Ellingsen et al., Am. J. Physiol. 265: 
LipofectamineTM (Gibco/BRL, Bethesda, Md.), DOTAPTM 	 H747-H754,1993) composed of DME, supplemented with 2 
(Boeringer-Mannheim, Indianapolis, Ind.) or analogous 	 mg/ml BSA, 2 mM L-camitine, 5 mM creatine, 5 mM taurine, 
compounds, liposomes, or an antibody that targets the DNA 
	 0.1 µM insulin, and 10 nM triiodothyronine with 100 IU/ml 
to a particular type of cell, e.g., a cardiomyocyte or an endot-  io penicillin and 100 µg/ml streptomycin. In experimental pro- 
helial cell. The method of administration may be any of those 	 tocols designed to examine myocyte survival and/or apopto- 
described in the Therapy section above. In particular, DNA 	 sis, insulin was omitted from the defined medium, which is 
for somatic gene therapy has been successfully delivered to 	 therefore termed "ACCTT". 
the heart by intravenous injection, cardiac perfusion, and 	 PCR Analysis of ErbB Receptors in Rat Heart 
direct injection into the myocardium (e.g., see Losordo et al., 15 	 cDNA sequences encoding portions of the C-termini of 
Circulation 98:2800-2804, 1998; Lin et al., Hypertension 	 ErbB receptors were amplified by using the following syn- 
33:219-224, 1999; Labhasetwar et al., J. Pharm. Sci. 	 thetic oligonucleotide primers: ErbB2A (5'-TGTGCTAGT- 
87:1347-1350, 1998; Yayama et al., Hypertension 31:1104- 	 CAAGAGTCCCAACCAC-3': sense; SEQ ID NO: 1) and 
1110, 1998). The therapeutic DNA is administered such that 	 ErbB2B (5'-CCTTCTCTCGGTAC TAAGTATTCAG-3': 
it enters the patient's cells and is expressed, and the vector- 20 antisense; SEQ ID NO: 2) for amplification of ErbB2 codon 
encoded therapeutic polypeptide binds to and activates car- 	 positions 857 to 1207 (Bargmann et al., Nature 319: 226-230, 
diomyocyte ErbB receptors. 	 1986); ErbB3A (5'-GCTTAAAGTGCTTGGCTCGGGT- 
The following Examples will assist those skilled in the art 
	 GTC-3: sense; SEQ ID NO: 3) and ErbB3B (5'-TCCTACA- 
to better understand the invention and its principles and 
	 CACTGACACTTTCTCTT-3': antisense; SEQ ID NO: 4) for 
advantages. It is intended that these Examples be illustrative 25 amplification of ErbB3 codon positions 712 to 1085 (Kraus et 
of the invention and not limit the scope thereof. 	 al., Proc. Natl. Acad. Sci. USA 86: 9193-9197, 1989); 
ErbB4A (5'-AATTCACCCATCAGAGTGACGTTTGG-3: 
Example I 	 sense; SEQ ID NO: 5) and ErbB4B (5'-TCCTGCAGG- 
TAGTCTGGGTGCTG: antisense; SEQ IDNO: 6) for ampli- 
General Methods 	 30 fication of ErbB4 codon positions 896 to 1262 (Plowman et 
al., Proc. Natl. Acad. Sci. USA 90: 1746-1750, 1993), RNA 
Preparation of Cardiac Myocyte and Non-Myocyte Pri- 	 samples (1 µg) from rat hearts or freshly isolated neonatal and 
mary Cultures 	 adult rat ventricular myocytes were reverse-transcribed to 
Neonatal rat ventricular myocyte (NRVM) primary cul- 	 generate first-strand cDNA. The PCR reactions were per- 
tures were prepared as described previously (Spriughorn et 35 formed in a final volume of 50 l containing approximately 50 
al., J. Biol. Chem. 267: 14360-14365, 1992). To selectively 	 ng of first-strand cDNAs for thirty cycles in a PTC-100TM 
enrich for myocytes, dissociated cells were centrifuged twice 	 Programmable Thermal Controller (M7 Research, Inc.; 
at 500 rpm for 5 min, pre-plated twice for 75 min, and finally 	 Watertown, Mass.). Each cycle included 30 sec at 94° C., 75 
plated at low density (0.7-1x104 cells/cm 2) in Dulbecco's 	 sec at 63° C., and 120 sec at 72° C. Thirty ld aliquots of each 
modified Eagle's (DME) medium (Life Technologies Inc., 4o reaction mixture were analyzed by electrophoresis in 1% 
Gaithersburg, Md.) supplemented with 7% fetal bovine 	 agarose gels and by ethidium bromide staining. The PCR 
serum (FBS) (Sigma, St. Louis, Mo.). Cytosine arabinoside 	 products were directly cloned into the TA cloning vector 
(AraC; 10 µM; Sigma) was added to cultures during the first 	 (Invitrogen Co., San Diego, Calif.) and verified by automatic 
24-48 h to prevent proliferation of non-myocytes, with the 	 DNA sequencing. 
exception of cultures used for thymidine uptake measure-  45 	 Analysis of ErbB Receptor Phosphorylation 
ments. Unless otherwise stated, all experiments were per- 	 To analyze which receptor subtypes were tyrosine-phos- 
formed 36-48 h after changing to a serum-free medium, DME 	 phorylated, neonatal and adult ventricular myocyte cells were 
plus ITS (insulin, transferrin, and selenium; Sigma). Using 	 maintained in serum-free medium for 24 to 48 h, and then 
this method, we routinely obtained primary cultures 	 treated with recombinant human glial growth factor 2 
with >95% myocytes, as assessed by microscopic observa-  50 (rhGGF2) at 20 ng/ml for 5 min at 37° C. Cells were quickly 
tion of spontaneous contraction and by immunofluorescence 	 rinsed twice with ice-cold phosphate-buffered saline (PBS) 
staining with a monoclonal anti-cardiac myosin heavy chain 	 and lysed in cold lysis buffer containing 1% NP40, 50 mM 
antibody (anti-MHC; Biogenesis, Sandown, N.H.). 	 Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM ethylene glycol-bis 
Primary cultures of cellular fractions isolated from neona- 	 ((3-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 1 
tal hearts enriched in non-myocyte cells were prepared by 55 mM ethylenediaminetetraacetic acid (EDTA), 0.5% sodium 
twice passaging cells that adhered to the tissue culture dish 
	
deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 10 
during the preplating procedure. These non-myocyte cul- 	 mM sodium molybdate, 8.8 g/L sodium pyrophosphate, 4 g/L 
tures, which contained few antiNHC-positive cells, were 	 NaFl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 
allowed to grow to subconfluence in DME supplemented with 	 µg/ml aprotinin, and 20 µM leupeptin. Lysates were centri- 
20% FBS before switching to DME-ITS for a subsequent 36 60 fuged at 12,000xg at 4° C. for 20 min, and aliquots of 500 µg 
to 48 h. 	 (neonatal myocytes) or 2000 µg (adult myocytes) of superna- 
Isolation and preparation of adult rat ventricular myocyte 	 tant were incubated with antibody specific to ErbB2 or ErbB4 
(ARVM) primary cultures was carried out using techniques 	 (Santa Cruz Biotechnology Inc., Santa Cruz, Calif.) over- 
previously described (Berger et al., Am. J. Physiol. 266: 	 night at 4° C. and precipitated with protein A-agarose (Santa 
H341-H349, 1994). Rod-shaped cardiac myocytes were 65 Cruz Biotechnology, Inc.). Immunoprecipitates were col- 
plated in culture medium on laminin (10 µg/ml; Collabora- 	 lected and released by boiling in sodium dodecyl sulfate 
tive Research, Bedford, Mass.) precoated dishes for 60 min, 	 (SDS) sample buffer. Samples were fractionated by SDS- 
US 8,394,761 B2 
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polyacrylamide gel electrophoresis (SDS-PAGE), transferred 
to polyvinylidene difluoride (PVDF) membranes (Biorad 
Laboratories, Hercules, Calif.) and probed with a PY20 
antiphosphotyrosine antibody (Santa Cruz Biotechnology, 
Inc.). For detection of ErbB2, the supernatants were also 5 
immunoprecipitated with a biotinylated RC20 antiphospho-
tyrosine antibody (Upstate Biotechnology, Inc., Lake Placid, 
N.Y.) and blotted with a monoclonal antibody to ErbB2 (Ab-
2; Oncogene Research Products, Cambridge, Mass.). 
Incorporation of [ 3H]Thymidine and [3H]Leucine 	 10 
As an index of DNA synthesis, [ 3H]thymidine incorpora-
tion was measured as described previously (Berk et al., 
Hypertension 13:305-314, 1989). After incubation for 36 to 
48 h in serum-free medium (DME plus ITS), the cells were 15 
stimulated with different concentrations of rhGGF2 (Cam-
bridge NeuroScience Co., Cambridge, Mass.) for 20 h. [ 3 H] 
thymidine (0.7 Ci/mmol; Dupont) was then added to the 
medium at a concentration of 5 µCi/ml and the cells were 
cultured for another 8 h. Cells were washed with PBS twice, 20 
10% TCA once, and 10% TCA was added to precipitate 
protein at 4° C. for 45 min. Parallel cultures of myocytes not 
exposed to rhGGF2 were harvested under the same condi-
tions as controls. The precipitate was washed twice with 95% 
ethanol, resuspended in 0.15 N NaOH and saturated with 1 M 25 
HCl, then aliquots were counted in a scintillation counter. The 
results are expressed as relative cpm/dish normalized to the 
mean cpm of control cells in each experiment. For antibody 
blocking experiments, the same procedure was applied 
except that the cells were preincubated with an antibody (0.5 30 
g/ml) specific for each neuregulin receptor (c-neu Ab-2, 
Oncogene Research Products; and ErbB3 or ErbB4, Santa 
Cruz Biotechnology), for 2 h prior to addition of either 
rhGGF2 or rhFGF2. 
The rate of [ 3H]leucine uptake was used as an index of 35 
protein synthesis. For these experiments, 10 µM cytosine 
arabinoside was added to the culture medium. Cells were 
grown in serum-free medium for 36 to 48 h and then stimu-
lated with different doses of rhGGF2. After 40 h, [ 3 H]leucine 
(5 µCi/ml) was added for 8 h, and cells were washed with PBS 40 
and harvested with 10% TCA. TCA-precipitable radioactiv- 
ity was determined by scintillation counting as above. 
5-Bromo-2'-Deoxy-Uridine Incorporation and Immunof-
luorescence Staining 
Nuclear 5-bromo-2'-deoxy-uridine (BrdU) incorporation 45 
and a cardiac muscle-specific antigen, myosin heavy chain 
(MHC), were simultaneously visualized using double-indi-
rect immunofluorescence. Primary NRVM cultures were 
maintained in DME plus ITS for 48 h and then stimulated 
with rhGGF2 (40 ng/ml) for 30 h. Control cultures were 50 
prepared similarly but without rhGGF2. BrdU (10 µM) was 
added for the last 24 h. Cells were fixed in a solution of 70% 
ethanol in 50 mM glycine buffer, pH 2.0, for 30 min at —20° 
C., rehydrated in PBS and incubated in 4 N HCl for 20 min. 
Cells were then neutralized with three washes in PBS, incu- 55 
bated with 1% FBS for 15 min, followed by a mouse mono-
clonal anti-MHC (1:300; Biogenesis, Sandown, N.H.) for 60 
min at 37° C. The primary antibody was detected with 
TRITC-conjugated goat anti-mouse IgG (1:300, The Jackson 
Laboratory, Bar Harbor, Me.), and nuclear BrdU incorpora- 60 
tion was detected with fluorescein-conjugated anti-BrdU 
antibody from an in situ cell proliferation kit (Boehringer 
Mannheim Co. Indianapolis, Ind.). The coverslips were 
mounted with Flu-mount (Fisher Scientific; Pittsburgh, Pa.), 
and examined by immunofluorescence microscopy. About 65 
500 myocytes were counted in each coverslip and the per-
centage of BrdU-positive myocytes was calculated. 
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For examination of changes in myocyte phenotype with 
rhGGF2, cells were fixed in 4% (w/v) paraformaldehyde for 
30 min at room temperature, rinsed with PBS, permeabilized 
with 0.1 % Triton X-100 for 15 min, and then incubated with 
1% FBS for another 15 min, followed by incubation with 
anti-MHC (1:300) and visualized with TRITC-conjugated 
(NRVM) or FITC-conjugated (ARVM) second antibody. 
ARVM were examined using a MRC 600 confocal micro-
scope (BioRad; Hercules, Calif.) with a Kr/Ar laser. 
Cell Survival Assay and Detection of Apoptosis 
Cell viability was determined by the 3-(4,5-dirnethylthi-
azol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma) 
cell respiration assay, which is dependent on mitochondrial 
activity in living cells (Mosman, J. Immunol. Meth. 65:55-63, 
1983). Primary cultures of NRVM after 2 days in serum-free 
medium were stimulated with different concentrations of 
rhGGF2 for either 4 or 6 days. ARVM were maintained in 
ACCTT medium or ACCTT medium plus different concen-
trations of rhGGF2 for 6 days. MTT was then incubated with 
the cells for 3 h at 37° C. Living cells transform the tetrazo-
lium ring into dark blue formazan crystals that can be quan-
tified by reading the optical density at 570 nm after cell lysis 
with dimethylsulfoxide (DMSO; Sigma). 
Apoptosis was detected in neonatal and adult myocytes 
using the terminal deoxynucleotidyltransferase (TdT)-medi-
ated dUTP nick end-labeling (TUNEL) assay. 3'-end label-
ling of DNA with fluorescein-conjugated dUTP was done 
using an in situ cell death detection kit (Boehringer Man-
nheim, Indianapolis, Ind.) following the manufacturer's 
instructions. Cells were counterstained with an anti-MHC 
antibody as described above, and the nuclei were also stained 
with Hoescht 33258 (10 µM, Sigma) for 5 min. More than 500 
myocytes were counted in each coverslip and the percentage 
of TUNEL positive myocytes was calculated. 
Flow cytometric analysis of neonatal myocytes fixed in 
70% ethanol/PBS and stained withpropidium iodide was also 
performed to quantify the percentage of cells undergoing 
apoptosis. This method is based upon the observation that 
cells undergoing apoptosis have a hypo-diploid quantity of 
DNA and localize in a broad area below the GO/GI peak on a 
DNA histogram. Briefly, cells were collected by trypsiniza-
tion, pooled with nonattached cells, and fixed in 70% ethanol. 
After being rinsed once with PBS, cells were incubated with 
a propidiurn iodide (20 µg/ml, Sigma) solution containing 
RNase A (5 Kunitz units/ml) at room temperature for 30 min. 
Data were collected using a FACScan (Becton-Dicicinson, 
San Jose, Calif.). For each sample, 10,000 events were col-
lected. Aggregated cells and extremely small cellular debris 
were gated out. 
Isolation and Hybridization of RNA 
Total cellular RNA was isolated by a modification of the 
acid guanidinium/thiocyanate phenol/chloroform extraction 
method (Chomczynski and Sacchi, Anal. Biochem. 162:156-
159, 1987) using the TRIZOL reagent (Life Technologies 
Inc., Gaithersburg, Md.). RNA was size-fractionated by 
formaldehyde agarose gel electrophoresis, transferred to 
nylon filters (Dupont, Boston, Mass.) by overnight capillary 
blotting and hybridized with cDNA probes labelled with 
[a 32P]dCTP by random priming (Life Technologies Inc.). 
The filters were washed under stringent conditions and 
exposed to X-ray film (Kodak X-OmatAR, Rochester, N.Y.). 
Signal intensity was determined by densitometry (Ultrascan 
XL, Pharmacia). The following cDNA probes were used: rat 
preproatrial natriuretic factor (prepro-ANF; a marker of car-
diomyocyte hypertrophy) (0.6 kb of coding region) 
(Seidman, et al., Science 225:324-326, 1984), andrat skeletal 
a-actin (240 by of a 3'-untranslated region) (Shari et al., 
US 8,394,761 B2 
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Nucleic Acids Res. 9:579-589, 1981). A rat glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; a housekeeping gene) 
cDNA probe (240 by of the coding region) (Tso et al., Nucleic 
Acids Res. 13:2485-2502, 1985) was used as control for load-
ing and transfer efficiency. 
Aortic Stenosis Model 
Ascending aortic stenosis was performed in male Wistar 
weanling rats (body weight 50-70 g, 3-4 weeks, obtained 
from Charles River Breeding Laboratories, Wilmington, 
Mass.), as previously described (Schunkert et al., Circulation, 
87:1328-1339, 1993; Weinberg et al. Circulation, 90:1410-
1422, 1994; Feldman et al., Circ. Res., 73:184-192, 1993; 
Schunkert et al., J. Clin. Invest. 96:2768-2774, 1995; Wein-
berg et al., Circulation, 95:1592-1600, 1997; Litwin et al., 
Circulation, 91:2642-2654; 1995). Sham-operated animals 
served as age-thatched controls. Aortic stenosis animals and 
age-matched sham-operated controls were sacrificed after 
anesthesia with intraperitoneal pentobarbital 65 mg/kg at 6 
and 22 weeks after surgery (n=20-29 per group). Hemody-
namic and echocardiographic studies in this model have 
shown that compensatory hypertrophy with normal left ven-
tricular (LU) cavity dimensions and contractile indices is 
present 6 weeks after banding, whereas animals develop early 
failure by 22 weeks after banding, which is characterized by 
onset of LU cavity enlargement and mild depression of ejec-
tion indices and pressure development per gram LU mass. In 
the present study, in vivo LU pressure measurements were 
perfomed prior to sacrifice as previously described 
(Schunkert et al., Circulation, 87:1328-1339,1993; Weinberg 
et al. Circulation, 90:1410-1422, 1994; Feldman et al., Circ. 
Res., 73:184-192, 1993; Schunkert et al., J. Clin. Invest. 
96:2768-2774, 1995; Weinberg et al., Circulation, 95:1592-
1600, 1997; Litwin et al., Circulation, 91:2642-2654; 1995). 
The animals were also inspected for clinical markers of heart 
failure, including the presence of tachypnea, ascites, and 
pleural effusions. Both body weight and LU weight were 
recorded. 
LU Myocyte Isolation for RNA Extraction 
In a subset of animals (n=10 per group), the heart was 
rapidly excised and attached to an aortic cannula. Myocyte 
dissociation by collagenase perfusion was performed as pre-
viously described (Kagaya et al., Circulation, 94:2915-2922, 
1996; Ito et al., J. Clin. Invest. 99:125-135, 1997; Tajima et 
al., Circulation, 99:127-135, 1999). To evalulate the percent-
age of myocytes in the final cell suspension, aliquots of myo-
cytes were fixed, pee ineabilized and blocked. The cell sus-
pension was then incubated with antibodies against 
a-sarcomeric actin (mAb, Sigma, 1:20) and von Willebrand 
Factor (pAb, Sigma, 1:200) to distinguish between myocytes 
and endothelial cells. Secondary antibodies (goat anti-rabbit, 
goat anti-mouse pAb, Molecular probes, 1:400) with a Texas 
Red (or Oregon Green) conjugate were used as a detection 
system. Ninety-eight percent myocytes and less than 2% frag-
ments of endothelial cells or unstained cells (fibroblasts) were 
routinely obtained. 
RNA Analysis 
Total RNA was isolated from control and hypertrophied 
myocytes (n=10 hearts in each group), and from LU tissue 
(n10 hearts in each group) using TRI Reagent (Sigma). 
Tissue and myocyte RNA were used for the following proto-
cols. Using myocyte RNA, Northern blots were used to assess 
message levels of atrial natriuretic peptide which were nor-
malized to GAPDH (Feldman et al., Circ. Res. 73:184-192, 
1993; Tajima et al., Circulation, 99:127-135, 1999). These 
experiments were done to confirm the specificity of myocyte 
origin of the RNA using this molecular marker of hypertro-
phy. 
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We also performed reverse transcription-polymerase chain 
reactions (RT-PCRs) for initial estimation of the presence of 
ErbB2, Erb 134 and neuregulin in samples derived from adult 
rat heart and adult myocytes using the following pairs of 
5 primers: ErbB2 sense 5' GCT GGC TCC GAT GTA TTT GAT 
GGT 3' (SEQ ID NO: 7), ErbB2 antisense 5' GTT CTC TGC 
CGT AGG TGT CCC TTT 3' (SEQ ID NO: 8) (Sarkar et al., 
Diagn. Mol. Pathol. 2:210-218, 1993); ErbB3 sense 5' GCT 
TAA AGT GCT TGG CTC GGG TGT C 3' (SEQ ID NO: 3), 
10 ErbB3 antisense 5' TCC TACACA CTGACA CTT TCT CTT 
3' (SEQ ID NO: 4) (Kraus et al., Proc. Natl. Acad. Sci. USA 
86:9193-9197; 1989), ErbB4 sense 5' AAT TCA CCC ATC 
AGA GTG ACG TTT GG 3' (SEQ ID NO: 5), ErbB4 anti- 
15 sense 5' TCC TGCAGG TAG TCT GGG TGC TG 3' (SEQ ID 
NO: 6) (Plowman et al., Proc. Natl. Acad. Sci. USA 90:1746-
1750; 1993); neuregulin sense 5' GCA TCA CTG GCT GAT 
TCT GGA G 3' (SEQ ID NO: 9), neuregulin antisense 5' CAC 
ATG CCG GTT ATG GTC AGC A 3' (SEQ ID NO: 10). The 
20 latter primers recognize nucleic acids encoded by the NRG-1 
gene, but do not discriminate between its isoforms. The 
amplification was initiated by 1 min of denaturation, 2 min of 
annealing at the gene specific temperature and 2 min exten-
sion at 72° C. The whole PCR reaction was electrophoresed 
25 on a 1% agarose gel and the PCR products of expected size 
were gel-purified. 
After cloning these fragments into pGEM-T vector 
(Promega, Madison, Wis.), the correctness and orientation of 
those fragments within the vector was confirmed by sequenc- 
30 ing. Cloned PCR fragments were used to generate a radiola-
beled riboprobe using the MAXIscript in vitro transcription 
kit (Ambion, Inc., Austin, Tex.) and a- 32P-UTP. Theplasmids 
containing the ErbB2, ErbB4 or neuregulin fragment were 
linearized and a radiolabeled probe was synthesized by in 
35 vitro transcription with T7 or T3 RNA polymerase. The R -ac-
tin probe provided by the kit was transcribed with T7 or T3 
polymerase and resulted in a 330 and 300 by fragment, 
respectively. 20 µg of total RNA was hybridized to 5x 10 5 cpm 
of ErbB2, ErbB4 or neuregulin c-RNA together with 2x10 4 
40 cpm of R -actin for later normalization according to the RPA II 
kit (Ambion) protocol. 
After digestion with RNase A/RNase TI, the samples were 
precipitated, dried, redissolved and finally separated on a 5% 
polyacrylamide gel for 2 hours. The gel was exposed to 
45 Kodak MR film for 12-48 hours, and the assay was quantified 
by densitometric scanning of the auto-radiograph using 
Image Quant software (Molecular Dynamics, Inc., Sunny-
vale, Calif.). ErbB2, ErbB4 and neuregulin mRNA levels 
were normalized to (3-actin. 
50 Western Blotting of ErbB2 and ErbB4 
LU tissue (n=5 hearts per group) was rapidly homogenized 
in a RIPA buffer containing 50 mmol/L Tris HCl, pH 7.4, 1 % 
NP-40, 0.1 % SDS, 0.25% Na-deoxycholate, 150 mM NaCl, l 
mM EDTA, 1 mM PMSF, 1 Aprotinin, 1 µg/ml leupeptin, 1 
55 µg/ml pepstatin and 1 mM Na 3PO4. Proteins were quantified 
using the Lowry assay kit (Sigma). 50 µg of protein in Laem-
mli SDS sample buffer were boiled for 5 minutes and after 
centrifugation loaded onto a 10% SDS-PAGE gel. After elec-
trophoresis, proteins were transferred to a nitrocellulose 
60 membrane at 100 mA overnight. The filters were blocked 
with 0.05% Tween-20, 5% nonfat milk and then incubated 
with anti-ErbB2 or anti-ErbB4 (Santa Cruz Biotechnology, 
each diluted 1:100, 1 µg/ml). After incubation with goat anti-
rabbit peroxidase-conjugated secondary antibody diluted 
65 1:2000, blots were subjected to the enhanced chemilumines-
cent (ECL) detection method (Amersham, Life Science) and 
afterwards exposed to Kodak MR film for 30-180 seconds. 
US 8,394,761 B2 
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Protein levels were normalized to protein levels of R -actin 
detected with anti-p-actin (Sigma). 
In Situ Hybridization for Neuregulin 
10-µm cryostat sections of left ventricular tissue (n=2 con-
trol and 6-week aortic stenosis hearts) were used for in situ 
hybridizations. Antisense and sense RNA probe was synthe-
sized from cDNA fragments in pBluescript with either T7 or 
T3 RNA polymerase and digoxigenin-labeled UTP (DIG 
RNA Labeling Mix, Boehringer Mannheim). Tissue sections 
were first treated with 4% paraformaldehyde for 20 minutes, 
followed by 30 minutes digestion with proteinase K (10 
µg/ml) at 37° C. and another 5 minutes of fixation in 4% 
paraformaldehyde. 
Following the fixation, the slides were washed in PBS three 
times for 5 minutes, after which the sections were immersed 
in 0.1 M triethanolamine chloride buffer with 0.25% acetic 
anhydride for 10 minutes to block polar and charged groups 
on the section and hence prevent nonspecific probe binding. 
After washing the slides in 2xSSC, they were then prehybrid-
ized (50%formamide, 2xSSC, 5% dextransulfate, 0.1% SDS, 
1 xDenhardt's, 400 µg/ml denatured salmon sperm DNA) at 
45° C. for 60 minutes in a moist chamber charged with 50% 
formamide/2xSSC. After 1 hour, the probes were addedto the 
prehybridization solution and the slides were hybridized for 
16-18 hours at 45° C. 
Following overnight hybridization, slides were twice 
washed in 4xSSC for 30 minutes at 45° C. while shaking, and 
then incubated with RNaseA (40 µg/ml) in 500 mM NaCl, 10 
mM Tris, 1 mM EDTA, pH 8.0, for 30 minutes at 37° C. to 
remove unhybridized probe. After RNase treatment, sections 
were immersed in 2xSSC at 50° C. for 30 minutes and then in 
0.2xSSC at the same temperature for another 30 minutes. The 
slides were equilibrated with TBS I buffer (100 mM Tris, 150 
mM NaCl pH 7.5) and then blocked with blocking reagent for 
30 minutes at room temperature according to the manufac-
turer's protocol (DIG Nucleic Acid Detection Kit, Boe-
hringer Mannheim). 
After removing the blocking reagent, the slides were 
immersed in TBS I for 1 minute and then the anti-DIG-AP 
conjugate solution (DIG Nucleic Acid Detection Kit, Boe-
hringer Mannheim) was applied to each section for 1.5 hours 
at room temperature in a humid chamber. Afterwards, the 
slides were washed in TBS I three times, 10 minutes per wash, 
to wash off the excess antibody and equilibrated in TBS II 
(100 mM Tris, 100 mM NaCl, pH 9.5, 50 mM MgC1 2 .7H2O) 
for 5 minutes. The color substrate was prepared according to 
the manufacturer's instructions and applied to each section 
until a blue-colored reaction became visible. The reaction 
was stopped and the slides were washed in PBS and distilled 
water for 5 minutes each. After a nuclear counter-staining the 
sections were dehydrated through an ethanol series, 
immersed in xylene and mounted by cover-slipping in Per-
mount. 
Statistical Analysis 
All values are expressed as mean±SEM. Statistical analy-
sis of differences observed between the aortic stenosis groups 
(6 and 22 weeks after banding) and the age-matched control 
groups was done by ANOVA comparison. An unpaired Stu-
dent's test was used for comparison among the groups at the 
same age post-banding. Statistical significance was accepted 
at the level of p<0.05. 
Example II 
Neuregulins Promote Survival and Growth of 
Cardiac Myocytes 
Expression of Neuregulin Receptors in the Heart 
To determine which of the NRG receptors (i.e., ErbB2, 
ErbB3, Erb134) are expressed in rat myocardium, RNA from 
16 
rat heart tissues at successive stages of development, and 
from freshly isolated neonatal and adult ventricular myo-
cytes, were reverse-transcribed and amplified by PCR, using 
primers that flank the variable C-termini of ErbB receptors. 
5 FIG. lA shows the semiquantitative RT-PCR analysis of neu-
regulin receptor mRNA levels during cardiac development. 
Total RNA from embryonic (E14, E16, and E19), neonatal 
(P 1) or adult (Ad) rat heart, and from freshly isolated neonatal 
rat ventricular myocytes (NRVM) or adult rat ventricular 
to myocytes (ARVM) was reverse-transcribed into cDNA and 
amplified with receptor isofonn-specific primers (see Meth-
ods). GAPDH was used as a control for reverse transcription, 
PCR amplification, and gel loading ("M" denotes 1 kb or 120 
15 by DNA molecular weight standards). The RT-PCR products 
were verified by DNA sequencing. 
All three ErbB receptors were expressed in the developing 
rat heart at mid-embryogenesis (E14), with the following 
rank order of their relative mRNA abundances: 
20 ErbB4>ErbB2>ErbB3. The expression of ErbB receptors 
was down-regulated later in embryogenesis. At El 6 and El 9,  
and at post-natal day 1 (PI), only ErbB2 and ErbB4 mRNAs 
could be detected. In adult rat heart, ErbB4 was still detect-
able, but its mRNA abundance was lower than that detected in 
25 embryonic and neonatal hearts, whereas ErbB2 mRNA and, 
rarely, ErbB3 mRNA could be detected only at low levels in 
adult myocardium. In freshly isolated neonatal and adult rat 
ventricular myocyte primary cultures, both ErbB2 and ErbB4 
mRNA were readily detectable by RT-PCR, although ErbB4 
30 
expression levels were consistently higher than those of 
ErbB2, Furthermore, when using receptor-specific cDNA 
probes for ErbB2, ErbB3 and ErbB4, only transcripts for 
ErbB4 were readily detectable in freshly isolated neonatal 
35 and adult rat ventricular myocytes by Northern blot. 
To determine which of the ErbB receptors were tyrosine-
phosphorylated following neuregulin treatment, primary cul-
tures of NRVM or ARVM, maintained in serum-free medium 
for 24 to 48 h, were treated either with or without neuregulin, 
40 i.e., recombinant human glial growth factor 2 (rhGGF2) (20 
ng/ml) for 5 min. ErbB4 receptor protein was immunopre-
cipitated with an anti-ErbB4 antibody from 500 µg of NRVM 
lysates or 2000 µg of ARVM lysates, and phosphorylated 
form of ErbB4 was detected by an anti -phosphotyrosine anti- 
45 body. The blot shown in FIG. 1B is representative of 3 inde-
pendent experiments. As shown in FIG. 113, phosphorylated 
ErbB4 is quite prominent in neonatal myocytes and less 
robust, but detectable, in adult myocytes, which is consistent 
with the levels of ErbB4 mRNA abundance we observed 
5o above. Phosphorylated forms of ErbB2 and ErbB3 could not 
be detected even if immunoprecipitated with biotinylated-
antipho sphotyro sine antibody, consistent with the much-re-
duced mRNA abundances for these two neuregulin receptors 
in post-natal cardiac myocytes. 
55 GGF2 Stimulates DNA Synthesis in Neonatal Rat Ven-
tricular Myocytes 
To investigate the ability of GGF2 to stimulate DNA syn-
thesis in NRVM primary cultures, myocytes maintained in 
serum-free medium for 2 days were subsequently treated with 
6o 40 ng/ml rhGGF2 for 30 h. DNA synthesis was monitored by 
measuring the incorporation of either BrdU (FIG. 213) or 
[3 H]thymidine (FIGS. 3A and 313), which were added to the 
media either 24 h or 8 h, respectively, before termination of 
each experiment. 
65 FIG. 2A shows myocyte myosin heavy chain in NRVM, 
visualized with a TRITC-conjugated goat anti-mouse anti-
body (red). FIG. 2B shows BrdU-positive nuclei visualized 
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with a fluorescein-conjugated mouse anti-BrdU antibody 	 50% of the increase in [3H]thymidine incorporation induced 
(green). The scale bar for FIGS. 2A and 2B is equilvalent to 	 by GGF2. A combination of these two antibodies had the 
10 µm. FIG. 2C shows the percentage of BrdU-positive myo- 	 same effect as either the anti-ErbB2 or anti-ErbB4 antibodies 
cytes under control conditions and in the presence of GGF2 	 alone. In contrast, an antibody to ErbB3 had no effect on 
(data are mean±SD for 3 experiments. *, p<0.01), As dis-  5 GGF2-induced DNA synthesis. To verify that the effects seen 
played in FIG. 2C, 40 ng/ml (approximately 0.7 nM) of 	 with the ErbB2 and ErhB4 antibodies were specific for GGF, 
rhGGF2 increased the percentage of BrdU-labelled myocytes 	 sister NRVM primary cultures were treated with 20 ng/ml 
(from postnatal day 1 rat heart ventricles) by about 80%, an 	 rhFGF2 (recombinant human bFGF). Neither antibody had 
increase in magnitude that was similar to that observed with 	 any effect on the approximately 2-fold increase in [3 H]thy- 
[3H]thymidine incorporation (FIG. 3A). 	 io midine incorporation with rhFGF2. These results suggest that 
FIGS. 3A and 3B show the effects of GGF2 on DNA 	 at least two of the known neuregulin receptor tyrosine kinases 
synthesis in myocyte-enriched and non-myocyte fractions 	 were present and coupled to downstream signalling cascades 
from rat ventricular myocyte primary isolates. In FIG. 3A, 	 in the neonatal ventricular myocyte. 
NRVM-enriched primary isolates or a "non-myocyte"-en- 	 GGF2 Promotes Cardiac Myocyte Survival In Vitro 
riched fraction (see Methods) were exposed to control (i.e., 15 	 During development, the net increase in the number of 
serum-free) medium alone (Ctl) or to medium containing 	 functional embryonic myocytes is dependent on both myo- 
either 40 ng/ml rhGGF2 (GGF) or 7% fetal bovine serum 	 cyte proliferative capacity and survival. Therefore, it was of 
(FBS). In FIG. 313, concentration-dependent effect of GGF2 	 interest to determine whether GGF2 could promote survival 
on NRVM DNA synthesis is shown. DNA synthesis was 	 of cardiac myocytes in addition to proliferation. Primary cul- 
assessed by [3H]thyrnidine incorporation, and the data are 20 tures of NRVM maintained in serum-free medium, with or 
expressed as relative cpm/dish normalized to the mean cpm of 	 without 10 µM of cytosine arabinoside (AraQ, were treated 
control cells in each experiment (mean±SD of triplicate 	 with the indicated concentrations of GGF2 for 4 days, and the 
analyses from three independent experiments; *, p<0.01 vs 	 relative numbers of metabolically active cells were deter- 
control). Twenty ng/ml of rhGGF2 provoked an approximate 	 mined by a MTT cell respiration assay (see Methods). Data 
60% increase in [3H]thymidine incorporation into NRVM, 25 are expressed as a percentage of the mean MTT activity of 
which was about half that observed with 7% FBS. The mito- 	 myocytes in triplicate culture dishes on day 0 at the time of the 
genic effect of rhGGF2 on NRVM was concentration-depen- 	 addition of GGF2. Data are shown as mean±SD (n=3 experi- 
dent, with about an 80% increase at 50 ng/ml (i.e., 0.9 nM) 	 ments; *, p<0.05 vs control). We observed that approximately 
(FIG. 313). GGF2 had similar mitogenic effects on BrdU or 	 25% of cells die by day 4. In contrast, addition of GGF2 
[3H]thymidine incorporation on rat embryonic ventricular 3o resulted in a 30% increase in MTT activity compared to 
myocytes (E19) and postnatal ventricular myocytes (P5), 	 controls. The effect was concentration-dependent with an 
whereas concentrations of GGF2 as high as 100 ng/ml had no 	 EC50 of 0.2 ng/ml (FIG. 5). This survival effect was observed 
effect on DNA synthesis in adult rat ventricular myocyte 	 in NRVM primary cultures for up to 7 days; it was also 
primary cultures. 	 observed in the presence of cytosine arabinoside (AraQ, an 
The effects of rhGGF2 on non-myocyte fractions obtained 35 antiproliferative agent. As shown in FIG. 5, the survival effect 
following the preplating steps of the neonatal rat ventricular 	 of GGF2 was observed at 4 days in the continuous presence of 
myocyte isolation procedure also were investigated. As 	 cytosine arabinoside, with about 90% myocyte viability in the 
shown in FIG. 3A, rhGGF2 did not induce any significant 	 presence of 50 ng/ml rhGGF2 compared to approximately 
change in [3H]thymidine incorporation into non-myocytes. 	 70% viability in control cultures. In contrast, GGF2 had no 
This was in contrast to 7% FBS, which induced nearly a 40 significant effect on the survival of myocyte-depleted, "non-
10-fold increase in [3 H]thymidine incorporation into this cell 	 myocyte"-enriched primary isolates at 4 days. 
population. Therefore, GGF2 shows a relatively specific 	 We examined next whether the survival effect of GGF2 was 
action on cardiac myocytes compared to a myocyte-depleted 	 mediated by inhibition of programmed cell death (apoptosis). 
cell population which, using the method of myocyte isolation 	 Primary cultures of NRVM 2 days in serum-free medium 
we employed here, is composed largely of fibroblasts and 45 were maintained in either the absence of rhGGF2 (FIGS. 
endothelial cells. 	 6A-6C) or in the presence of 20 ng/ml of rhGGF2 (FIGS. 
To determine which of the known neuregulin receptors 	 6E-6G) for 4 days. Cells were then fixed and stained with 
mediate the mitogenic effect of GGF2 on fetal and neonatal 	 anti-MHC antibody and a TRITC-conjugated secondary anti- 
ventricular myocytes, DNA synthesis was measured in pri- 	 body to visualize myocytes (FIGS. 6A and 6E) or with fluo- 
mary NRVM cultures after incubation with antibodies spe-  5o rescein-conjugated dUTP (i.e., TUNEL) to reveal apoptotic 
cific for ErbB2, ErbB3 and ErbB4. Neonatal myocytes were 	 cells (FIGS. 6B and 6F). The TUNEL-positive myocytes 
cultured for two days in serum-free medium, after which they 	 displayed cell shrinkage and chromatin condensation, which 
were treated for 30 h either without (control), or with rhGGF2 	 were also identified by Hoescht 33258-staining (FIGS. 6C 
(10 ng/ml), or with rhFGF2 (20 ng/ml), or with GGF2/FGF2 	 and 6G). Apoptosis was quantified either by counting the 
and antibodies to ErbB2, ErbB3 or ErbB4, either alone or in 55 number of TUNEL-positive myocytes (FIG. 6D) or by flow 
combination as illustrated. Antibodies (0.5 µg/ml/antibody) 	 cytometry analysis of the sub-GI fraction following pro- 
were preincubated with cells for 2 h before the addition of 	 pidium iodine-staining of primary NRVM cultures that had 
either GGF2 or FGF2. [3 H]Thymidine was added during the 	 been treated for 4 days with the indicated concentrations of 
last 8 h (data are expressed as relative cpm/dish normalized to 	 rhGGF2 (H). The data shown for FIG. 6D and FIG. 6H are 
the mean cpm of control cells in each experiment, and are 60 given as mean±S.D for three independent experiments. The 
presented as mean±SD; n=3 independent experiments; *, 	 scale bar in FIGS. 6A-6C and 6E-6G represents 10 µM. 
p<0.04 vs rhGGF2 alone; #, p>0.1 vs rhGGF2 alone). 	 After 6 days in serum-free medium, about 17% of NRVM 
As shown in FIG. 4, a monoclonal antibody against the 	 maintained under control conditions at low density (i.e., sub- 
extracellular domain of c-neu/ErbB2, inhibited the GGF2- 	 confluent) exhibited evidence of apoptosis as detected by 
dependents increase in [3H]thymidine incorporation into 65 TUNEL staining, with small condensed nuclei and cell 
NRVM by GGF2 could be inhibited. Similarly, an antibody 	 shrinkage consistent with apoptotic cell death (FIGS. 6A-6C 
directed against the C-terminus of ErbB4 also blocked about 	 and 6E-6G). In the presence of 20 ng/ml rhGGF2, the number 
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of TUNEL positive myocytes declined to about 8% (FIG. 
6D). The effect of GGF2 on inhibiting apoptosis was also 
quantified using flow cytometric analysis of propidium 
iodide-labelled NRVM primary cultures. After 4 days in 
serum- and insulin-free medium, 22% of NRVM were hypo-
diploid, consistent with initiation of programmed cell death. 
In the presence of rhGGF2 at concentrations above 10 ng/ml, 
less than 10% of NRVM exhibited evidence of apoptosis 
(FIG. 6H). 
The survival and antiapoptotic effects of GGF2 on the adult 
rat ventricular myocyte (ARVM) were also examined by 
MTT cell respiration assay and TUNEL staining. In the 
experiment shown in FIG. 7A, primary cultures of ARVM 
were maintained in either a serum- and insulin-free medium 
"ACCTT", see Methods), or ACCTT medium plus GGF2 for 
6 days. The number of metabolically active cells was deter-
mined by the MTT cell respiration assay, and the data are 
expressed as the relative absorbance normalized to the mean 
absorbance of untreated, control cells. Each bar represents the 
mean±S.D (n=3 experiments; *, p<0.05 vs control). In the 
experiment shown in FIG. 713, primary cultures of ARVM 
were maintained in ACCTT medium (control) or ACCTT 
medium plus rhGGF2 (25 ng/ml) for 3 days. After fixation 
with 4% paraformaldehyde, myocytes were visualized with 
an anti-MHC antibody and a TRITC-conjugated secondary 
antibody, and apoptotic cells were identified by TUNEL 
staining. About 500 myocytes were counted on each coverslip 
(data are mean±S.D of three independent experiments; 
p<0.05 versus control). When compared to untreated ARVM 
primary cultures, in which more than 10% of cells were 
positive for TUNEL labelling, rhGGF2 (20 ng/ml)-treated 
adult myocyte cultures exhibited only about 3% TUNEL-
positive staining (FIG. 713). These results indicate neuregu-
lins act as survival factors at least in part by preventing pro-
grammed cell death in both neonatal and adult ventricular 
myocytes. 
GGF2 Induces Hypertrophic Growth of Cardiac Myocytes 
In order to investigate whether neuregulin signalling can 
induce a hypertrophic (growth) response in cardiac myocytes, 
we examined the effects of GGF2 on induction of myocyte 
hypertrophy in both neonatal and adult rat ventricular myo-
cyte primary cultures. FIGS. 8A and 8B show photomicro-
graphs of subconfluent NRVM primary isolates incubated 
either without (FIG. 8A) or with (FIG. 813) rhGGF2 (20 
ng/ml) for 72 h in serum-free medium, after which cells were 
fixed and stained with an antibody to cardiac MHC (red, 
TRITC) and examined using indirect immunofluorescence 
microscopy. The scale bar shown in the figure represents 10 
µM. After a 72-hr incubation in serum-free medium with 20 
ng/ml (i.e., 0.36 nM) of rhGGF2, neonatal cardiac myocytes 
(NRVM) exhibited a significant increase in cell size and in 
myofibrillar development. 
A hypertrophic response in cardiac myocytes is character-
ized by a number of phenotypic changes in addition to an 
increase in cell size, such as an increase in contractile protein 
content without cellular proliferation and the re-activation of 
an "embryonic" gene program. Therefore, we examined the 
effects of neuregulin on levels of prepro-ANF and skeletal 
a-actin mRNA (transcripts normally found in relatively low 
abundance in neonatal and adult ventricular myocytes), and 
on [3H]leucine incorporation as an index of protein synthesis 
in NRVM primary cultures. FIG. 8C shows a Northern blot 
analysis for prepro-ANF and skeletal a-actin mRNA from 
total RNA (20 µg/lane) from NRVM incubated either with or 
without rhGGF2 (20 ng/ml) for the times indicated. Equal 
loading and transfer of RNA were confirmed by GAPDH 
hybridization. RhGGF2 (20 ng/ml) increased mRNA levels 
for prepro-ANF and skeletal-actin within 60 min, approxi-
mately doubling by 16 h. 
To test the effect of GGF2 on protein synthesis, NVRM 
were cultured in serum free medium for 24 h, after which they 
were treated with the indicated concentrations of rhGGF2 for 
40 h, and pulsed with [3H]leucine for 8 h before termination 
5 of GGF2 stimulation. The incorporation of [3 H]leucine at 
each concentration of GGF2 was normalized to the protein 
content of each dish, and data are expressed as relative cpm/ 
dish normalized to the mean cpm of untreated control cells in 
each experiment (mean±S.D.; n=3 experiments; *, p<0.01 vs 
io control). FIG. 8D shows that GGF2 also stimulated [3 H] 
leucine incorporation, with about a 120% increase at 48 h, at 
a concentration of 5 ng/ml. To minimize possible confound-
ing effects of GGF2 on the rate of [3H]leucine uptake into 
non-myocyte contaminant cells, these experiments were 
15 repeated in the continuous presence of cytosine arabinoside 
with similar results. 
GGF2 also caused hypertrophic responses in cultured adult 
rat ventricular myocytes (ARVM). Primary cultures of 
ARVM were plated on coverslips in 24-well dishes and main- 
20 tained for 5 days in ACCITT medium either without (FIG. 
9A) or with rhGGF2 (20 ng/ml) (FIGS. 9B and 9C). Cells 
were fixed in 4% paraformaldehyde, stained with an antibody 
to myosin heavy chain (green, FITC), and examined by con-
focal microscopy. The scale bars represent 10 µM. By 72 h in 
25 the continuous presence of 20 ng/ml of rhGGF2, some adult 
myocytes had begun to develop "pseudopod"-like extensions, 
primarily from the region of the intercalated discs, and by 5 
days, more than 60% of the GGF-treated adult cardiomyo-
cytes displayed phenotypic changes consistent with those 
30 illustrated in FIGS. 9B and 9C, whereas more than 80% of 
untreated ARVM maintained the phenotype exhibited in FIG. 
9A. 
GGF2 also enhanced expression of prepro-ANF and skel-
etal a-actin in ARVM. Primary isolates of ARVM were 
35 stimulated either with or without 20 ng/ml rhGGF2 for the 
times indicated. Total RNA was isolated and analyzed by 
Northern blot (25 µg/lane) using prepro-ANF and skeletal 
a-actin cDNA probes. Equal loading and transfer conditions 
were confirmed by GAPDH hybridization. Phenylephrine 
40 (PE, 10 µM) was used as a positive control for hypertrophic 
growth. As shown in FIG. 9D, rhGGF2 (20 ng/ml) doubled 
prepro-ANF mRNA abundance in ARVM primary cultures 
after 8 h, and this had increased 3- to 4-fold within 20 h. An 
increase in skeletal a-actin mRNA abundance was also 
45 observed that was greater than that seen with phenylephrine 
(10 µM), an a-adrenergic agonist known to induce hyper-
trophic growth and reexpression of a number of fetal genes in 
adult rat ventricular myocytes. Within 7 h, skeletal a-actin 
mRNA levels were easily detectable, and increased by an 
5o additional 250% by 30 h treatment with GGF2. Neither GGF2 
nor phenylephrine had any effect on GAPDH mRNA abun-
dance under the conditions employed here. 
To test the effect of GGF2 on protein synthesis, ARVM (2 
days in ACCITT medium) were stimulated with increasing 
55 concentrations of rhGGF2 for 40 h and [3 H]leucine was 
added during the last 14 h. [3H]Leucine uptake in GGF2-
treated cultures was normalized to the mean of [3H]-leucine 
uptake in non-stimulated control myocytes. Data were also 
normalized to protein content of each dish to adjust for any 
60 variability in cell number among dishes (mean±SD; n=4; *, 
p<0.01 vs control). As illustrated in FIG. 9E, GGF2 induced 
a dose-dependent increase in [3 H]leucine incorporation, with 
a 70% increase at a concentration of 5 ng/ml. Thus, this 
neuregulin induces phenotypic changes consistent with 
65 hypertrophic adaptation in both neonatal and adult rat ven-
tricular myocyte phenotypes at subnanomolar concentra-
tions. 
US 8,394,761 B2 
21 
Example III 
ErbB2 and ErbB4 Expression Levels Decrease in 
Aortic Stenosis Rats in Transition from Chronic 
Hypertrophy to Early Heart Failure 
22 
TABLE 1-continued 
Left Ventricular Hypertrophy and Hemodynamics 
	
C (6 wks) 	 LVH (6 wks) C (22-wks) LVH (22 wks) 
	
LVdevP/g 84.2 ± 5.2 	 108.1 ± 6.8* 	 82.4 ± 7.8 	 68.1 ± 4.2* 
(-Hg/g) 
LV Hypertrophy and Hemodynamics Table 1 Legend: LVH, hearts with left ventricular hypertrophy, 6 and 22 weeks after aortic stenosis; 
10 	 C, age-matched controls; 
As shown in Table 1, left ventricular (LV) weight and the BW, body weight; 
LV/body weight ratio were significantly (p<0.05) increased 
LV Wt, left ventricular weight; 
LVEOP, LV end-diastolic pressure ; 
in the 6-week and 22-week aortic stenosis animals compared LVSP, LV systolic pressure ; 
with age-matched controls. The in vivo LV systolic pressure 
LV devP, LV developed pressure per gram. 
values are mean •_ sEM; 
was significantly increased in both 6-week and 22-week aor- 
15 
*p <0.05 vs. a ge-matched controls ; 
tic stenosis animals compared with age-matched controls. In 
p < 0.05 vs. 6-weeks LVH. 
n =14-20 per group. 
vivo LV end-diastolic pressure was also higher in aortic 
stenosis animals compared to age-matched controls. Consis- Expression of LV ErbB2, ErbB4 and Neuregulin in Aortic Stenosis 
tent with prior studies in this model, LV systolic developed 20 	 Using RT-PCR, we were able to detect ErbB2, ErbB4 and 
pressure per gram was significantly higher in 6-week aortic neuregulin mRNA, but not ErbB3 mRNA, in LV tissue 
stenosis animals in comparison with age-matched controls, derived from hearts of adult male rats with and without left 
but depressed in 22-week aortic stenosis animals. At 22-week ventricular hypertrophy, as well as in normal and hypertro- 
post banding, the aortic stenosis animals also showed clinical 25 phied myocytes. FIG. 10A shows a ribonuclease protection 
markers of failure including tachypnea, small pleural and assay demonstrating LV ErbB2 and R -actin mRNA expres- 
pericardial effusions. sion in 6-week aortic stenosis hearts and controls, and in 
22-week aortic stenosis hearts and controls. FIG. 10B shows 
TABLE 1 a ribonuclease protection assay demonstrating LV ErbB4 and 
30 R -actin mRNA expression in 6-week aortic stenosis hearts 
and controls, and 22-week aortic stenosis hearts and controls. 
Left ventricular Hypertrophy and Hemodynamics Steady state levels of ErbB2, ErbB4 and neuregulin mRNA 
levels in LV tissue from aortic stenosis rats and controls (n=5 
C (6 wks) 	 LVH (6 wks) 	 C (22-wks) 	 LVH (22 wks) hearts per group) were then measured by ribonuclease pro- 
35 tection assay (RPA) and normalized to (3-actin. The LV neu- 
BW (g) 	 397 ._ 10 	 378 ._ 15 	 590 ._ 10 	 564 ._ 19 regulin mRNA levels were not significantly different in tissue 
LV wt (g) 	 1.25 ._ 0.05 	 1.58 ._ 0.06* 	 1.64 ._ 0.07 	 2.46 ._ 0.10* from 6-week aortic stenosis rats compared to age-matched 
controls (0.68±0.12 vs. 0.45±0.12 units, NS) or 22-week LV Wt/ 	 3.18 ± 0.13 	 4.40 ± 0.21* 	 2.84 ± 0.14 	 4.41 ± 0.20* 
aortic stenosis rats compared to age-matched controls 
BW (g/kg) 40 (0.78±0.21 vs. 0.51±0.21 units, NS). Moreover, the LV 
LVEDP 	 4.8 ._ 0.3 	 12.4 ._ 0.7* 	 6.5 ._ 0.8 	 15.7 ._ 1.0* ErbB2 and ErbB4 mRNA levels, which were normalized to 
(-Hg) levels of (3-actin, were preservedin 6-weekaortic stenosis rats 
LVSP 	 104 -_ 3 	 181 -_ 7* 	 129 -_ 5 	 182 -_ 9* with compensatory hypertrophy relative to controls. In con- 
(-Hg) 45 trast, LV ErbB2 (p<0.05) and ErbB4 (p<0.01) message levels 
were significantly depressed in 22-week aortic stenosis rats at 
the stage of early failure (FIG. 10 and Table 2). 
TABLE 2 
LV mRNA and Protein Levels of ErbB Receptors 
C (6 wks) 	 LVH (6 wks) C (22-wks) 	 LVH (22 wks) 
mRNA (LV) 
ErbB2 	 0.354 ± 0.016 	 0.326 ± 0.028 	 0.528 ± 0.072 	 0.301 ± 0.027* 
ErbB4 	 1.158 ± 0.036 	 1.088 ± 0.062 	 1.236 ± 0.050 	 0.777 ± 0.082** 
mRNA (myocyte) 
ErbB2 	 0.755 ± 0.066 	 0.683 ± 0.027 	 1.609 ± 0.089 	 0.493 ± 0.035** 
ErbB4 	 0.291 ± 0.024 	 0.266 ± 0.012 	 0.346 ± 0.023 	 0.182 ± 0.014** 
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TABLE 2-continued 
LV mRNA and Protein Levels of ErbB Receptors 
C (6 wks) 	 LVH (6 wks) C (22-wks) 	 LVH (22 wks) 
protein (LV) 
ErbB2 	 1.228 ± 0.107 	 1.073 ± 0.092 	 1.218 ± 0.198 	 0.638 ± 0.065* 
ErbB4 	 2.148 ± 0.180 	 1.968 ± 0.150 	 1.446 ± 0.119 	 0.828 ± 0.068** 
Table 2 Legend: 
LVH, hearts with left ventricular hypertrophy, 6 and 22 weeks after aortic stenosis; 
C, age-matched controls; 
left ventricular (LV) mRNA levels were measured by ribonuclease protection assay and normalized to P-actin; 
mRNA levels were measured in RNA from both LV tissue (mRNA, LV; 
n = 5 hearts per group) and from LV myocytes (mRNA, myocyte; 
ErbB2 n = 5 hearts per group; 
ErbB4 n = 3-4 hearts per group). 
LV protein levels were measured in LV tissue to = 5 per group) by Western blotting and normalized to P -actin. 
Values are mean ± SEM; 
*p < 0.05 vs. age matched controls; 
**p <0.01 vs. age-matched controls. 
We next examined gene expression in RNA from LV myo-
cytes of 6-week and 22-week aortic stenosis animals and 
controls. The specificity of expression in myocytes was deter-
mined by examining message levels of atrial natriuretic pep-
tide (ANP), a positive molecular marker of pressure overload 
hypertrophy, using myocyte RNA and normalization to levels 
of GAPDH. As shown in FIG. 11, ANP was upregulated in 
myocytes from both 6-week (710±16 vs. 230±40 units, 
p<0.05) and 22-weeks aortic stenosis animals (898±52 vs. 
339±13 units, p<0.05) in comparison with controls (n=5 per 
group). Neuregulin was not detectable by RPA in RNA 
derived from myocytes in any group. 
ErbB2 (n=5 per group) and ErbB4 (n=3-4 per group) mes-
sage levels were also measured in myocyte RNA from both 
aortic stenosis groups (FIG. 12 and Table 2), FIG. 12A shows 
a ribonuclease protection assay demonstrating LV myocyte 
ErbB2 and R -actin mRNA expression in 6-weeks aortic 
stenosis hearts and controls, and 22-weeks aortic stenosis 
hearts and controls. FIG. 12B shows a ribonuclease protec-
tion assay demonstrating LV myocyte ErbB4 and R -actin 
mRNA expression in 6-week aortic stenosis hearts and con-
trols, and 22-week aortic stenosis hearts and controls. Con-
sistent with the measurements in LV tissues samples, cardi-
omyocyte ErbB2 and ErbB4 mRNA levels, normalized to 
R -actin levels, are preserved relative to controls in 6-week 
aortic stenosis animals at the stage of compensatory hyper-
trophy (NS). However, both ErbB2 and ErbB4 expression are 
significantly downregulated in 22-week aortic stenosis ani-
mals at the transition to failure (p<0.01). 
LV ErbB2 and ErbB4 Protein Levels 
Western blotting using polyclonal antibodies for ErbB2 
and ErbB4 was performed using protein samples derived 
from LV tissue of 6-week and 22-week aortic stenosis rats in 
comparison with age-matched controls (n=5 per group). 
FIGS. 13A and 13B show Western blots showing LV ErbB2 
and R -actin protein levels in 6-week (FIG. 13A) aortic steno-
sis hearts and controls, and 22-week (FIG. 13B) aortic steno-
sis hearts and controls. FIGS. 13C and 13D show Western 
blots showing LV ErbB4 and R -actin protein levels in 6-week 
(FIG. 13C) aortic stenosis hearts and controls, and 22-week 
(FIG. 13D) aortic stenosis hearts and controls. Densitometnc 
signals of each receptor were normalized to signals of R  -actin. 
As shown in FIGS. 13A-13D and Table 2, ErbB2 and ErbB4 
mRNA expression is preserved relative to controls in 6-weeks 
aortic stenosis animals at the stage of compensatory hyper-
trophy (NS) but ErbB2 (p<0.05) and ErbB4 (p<0.01) are  
20 
downregulated in 22-week aortic stenosis animals during 
early failure. Thus, a decrease in both LV message andprotein 
levels of ErbB2 and ErbB4 is present at the stage of early 
failure in this model of pressure overload. 
25 In Situ Hybridization for Neuregulin 
Antisense digoxigenin-labeled mRNA of neuregulin gen-
erated reproducible hybridization signals on LV cryosections, 
whereas the corresponding sense transcript generated no sig- 
30 
nal above background. Neuregulin signals inadultheart cryo-
sections were observed in the endothelial cells of the cardiac 
microvasculature with minimal or no signal in other cell 
compartments. There was no difference between control and 
aortic stenosis animals. 
35 
Example IV 
Inhibition of Heart Failure in Aortic Stenosis Mice 
by Polypeptides that Contain a Neuregulin-1 
40 	 EGF-Like Domain 
The Examples above describe data showing that rhGGF2 
suppresses apoptosis and stimulates cardiomyocyte hypertro-
phy in an ErbB2- and ErbB4-dependent fashion. Moreover, 
45 ErbB2 and ErbB4 receptors are down-regulated in the left 
ventricles of rats with pressure overload-induced heart fail-
ure. Cardiomyocyte apoptosis is extremely rare during the 
early compensatory hypertrophic stage in aortic stenosis mice 
(i.e., 4 weeks after aortic banding), but consistently appears 
5o during the transition to early heart failure (i.e., 7 weeks after 
aortic banding). 
These above observations indicate that administration of 
polypeptides that have an EGF-like domain encoded by a 
neuregulin gene will be useful in inhibiting the progression of 
55 and/or protecting against congestive heart failure. While not 
wishing to be bound by theory, it is likely that neuregulin 
treatment will strengthen the pumping ability of the heart by 
stimulating cardiomyocyte hypertrophy, and partially or 
completely prevent further deterioration of the heart by sup- 
60 pressing cardiomyocyte apoptosis. 
One of ordinary skill in the art can readily determine the 
optimal dosage regimen required for providing prophylaxis 
against congestive heart disease or for slowing or halting 
progression of already-existent heart disease, using one of the 
65 many animals models for congestive heart failure that are 
known in the art. For example, as a starting point, the relative 
efficacy of a 0.3 mg/kg dose of GGF2 administered at early 
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stages and late stages of cardiac disease in the aortic stenosis 	 sary for the cytoprotective effect of IGF on myocytes. How- 
mouse model may be assessed as follows. 	 ever, the lack of cytoprotection by NRG-1 over the same time 
Group 1 (n-6); treated: injections ofrhGGF2 (0.3 mg/kg 	 course indicates that activation of PI-3 kinase and Akt is not 
given on alternate days), initiated 48 hours after aortic band- 	 sufficient for cytoprotection. The relatively long NRG-1 
ing and continued through week 7. 	 5 exposure period needed for cytoprotection suggests that 
Group 2 (n-6); treated: injections ofrhGGF2 (0.3 mg/kg 	 NRG-1-dependent protection of cardiomyocytes against apo- 
given on alternate days), initiated at the beginning of week 4 	 ptosis requires de novo protein synthesis. Consistent with this 
after aortic banding and continued through week 7. 	 observation, treatment of the cells with cyclohexamide inhib- 
Group 3 (n=6); control: sham injections, initiated 48 hours 	 its the anti-apoptotic effect of NRG-1 on cardiomyocytes. 
after aortic banding and continued through week 7. 	 10 	 The results described above show that NRG-1 effectively 
Group 4 (n-6); control: sham injections, initiated at the 	 inhibits anthracycline-induced apoptosis. Therefore, NRG-1 
beginning of week 4 after aortic banding and continued 	 could be used to limit or prevent cardiotoxicity in patients 
through week 7. 	 undergoing anthracycline chemotherapy and to treat patients 
Animals are sacrificed at the end of week 7. Prior to sacri- 	 have congestive heart failure caused by cardiotoxicity 
fice, left ventricular hemodynamics are measured as 15 induced by anthracyclines or other cardiotoxic agents. 
described in Example I above, or using any standard protocol. 	 Existing in the art are various well known animal models of 
Confocal microscopy may be used to quantitate myocyte 	 anthracycline-induced cardiotoxicity. Mouse, rat, rabbit, 
growth (hypertrophy) and myocyte apoptosis by in situ nick- 	 hamster, dog, swine, and monkey models for assessing the 
end labeling (TUNEL) or similar techniques for measuring 	 relative efficacy of therapeutic compounds for ameliorating 
cell death, using standard protocols or as described in 20 anthracycline-induced cardiotoxicity are described in `Ame- 
Example 1. 	 lioration of Chemotherapy Induced Cardiotoxicity" Semin. 
One of skill in the art will fully comprehend and know how 	 Oncol. 25(4)Suppl. 10, August 1998 (see, e.g., Myers, Semin. 
to perform the experiments needed to determine the optimal 
	
Oncol. 25:10-14, 1998; Herman and Ferrans, Semin. Oncol. 
neuregulin dosage regimen (e.g., amount of dose, frequency 	 25:15-21, 1998; and Imondi, Semin. Oncol. 25:22-30,1998). 
of administration, optimal time during the disease course to 25 These models may be used to determine the optimal neuregu- 
initiate neuregulin treatment) for minimizing, preventing, or 	 lin or neuregulin-like polypeptide treatment regimen (e.g., 
even reversing congestive heart disease. 	 amount and frequency of dosage, and timing relative to 
anthracycline administration), for minimizing, preventing, or 
Example V 	 reversing anthracycline-induced cardiotocicity. 
30 
NRG-1 Inhibits Anthracycline-Induced Apoptosis in 	 Example VI 
Rat Cardiac Myocytes 
Neuregulin-Dependent Inhibition of Cardiac Failure 
The anthracycline antibiotics (e.g., daunorubicin, and 	 by Anthracycline/Anti-ErbB2 (Anti-HER2) 
doxorubicin) have been a mainstay of cancer chemotherapy 35 	 Combination Therapy 
for more than 20 years. However, the short- and long-term 
cardiotoxicity of these drugs limits both the individual dose 	 Various types of cancer cells display increased expression 
and the cumulative dose that can be delivered to a patient. 	 or increased biological activity of ErbB receptors. These 
There are two clinical types of anthracycline-induced car- 	 transmembrane receptor tyrosine kinases bind growth factors 
diotoxicity. The acute type, which can occur after a single 4o belonging to the neuregulin (also known as heregulin) family. 
dose of anthracycline, is characterized by electrocardio- 	 Expression of the ErbB2 receptor (also known as HER2 and 
graphic changes, arrhythmias, and a reversible decrease in 	 neu) in cancer cells has been correlated with increases in 
ventricular contractile function. The chronic, delayed type is 	 proliferation of carcinoma cells derived from various tissues, 
characterized by a largely irreversible decrease in ventricular 	 including, but not limited to, breast, ovary, prostate, colon, 
contractile function which progresses to dilated cardiomy-  45 pancreas, and salivary gland. 
opathy and congestive heart failure. The incidence of this 	 Recently, it has been shown that HERCEPTIN® (Trastu- 
chronic cardiotoxicity is in direct proportion to the cumula- 	 zumab; Genentech, Inc., South San Franciico, Calif.), a 
tive anthracycline dose. 	 humanized monoclonal antibody that specifically binds the 
We have found that GGF2 (NRG-1) inhibits anthracycline- 	 extracellular domain of the human ErbB2 (HER2) receptor, 
induced apoptosis in rat cardiac myocytes. FIG. 14 shows that 50 inhibits the growth of breast carcinoma cells in vitro and in 
rat cardiomyocyte cultures pre-treated with IGF-1 or NRG-1 	 vivo by down-regulating ErbB2 activity. A Phase III clinical 
are less susceptible to apoptosis (indicated by TUNEL stain- 	 trial evaluating the safety and efficacy of combining HER- 
ing) induced by 1 µM daunorubicin. For IGF-1 this protective 	 CEPTIN® therapy with traditional anthracycline (doxorubi- 
effect is rapid, and can be achieved within 30 minutes of 	 cin) chemotherapy in breast cancer patients showed that 
pre-incubation, similar to what was reported for fetal cardiac 55 patients receiving the combination therapy displayed greater 
myocytes. In contrast, this effect takes 24 hours of pre-incu- 	 tumor shrinkage and inhibition of cancer progression than 
bation with NRG-1. 	 patients receiving either therapy alone. However, patients 
FIG. 15A shows that both IGF-1 and NRG-1 cause rapid 	 receiving combination therapy also suffered increased car- 
phosphorylation of Akt (FIG. 15A), and that this is inhibited 	 diotoxicity relative to patients receiving anthracycline 
by the PI-3 kinase inhibitor wortmannin. Akt has been impli-  60 therapy alone, indicating that anti-ErbB2 (anti-HER2) anti- 
cated in mediating survival signals in some systems through 
	
bodies such as HERCEPTIN® increase anthracycline-in- 
phosphorylation and inactivation of the pro-apoptotic protein 	 duced cardiotoxicity. In addition, patients that had previously 
caspase 3. Either thirty minutes of pre-incubation with IGF4 
	
been treated with doxorubicin and later received HERCEP- 
or 24 hours of pre-incubation with NRG-1 prevent anthracy- 	 TIN® also showed an increased incidence of cardiotoxicity, 
cline-induced activation of caspase 3. This effect, as well as 65 relative to patients treated with doxorubicin alone. 
the survival effect of IGF-1, is completely prevented by wort- 	 Given the recently-shown success of HERCEPTIN® fan- 
mannin (FIG. 1513). Thus, activation of PI-3 kinase is neces- 	 thracycline combination therapy in ameliorating Erb132-over- 
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expressing breast tumors, it is likely that similar combination 	 Other Embodiments 
therapies will soon be used to treat other ErbB2-overexpress- 
ing tumors. However, the benefit/risk ratio of anti-ErbB2 	 All publications and patent applications mentioned in this 
antibody/anthracycline combination therapy would be 	 specification are herein incorporated by reference to the same 
greatly improved if its associated cardiotoxicity could be 5 extent as if each independent publication or patent applica-
decreased or prevented. 	 tion was specifically and individually indicated to be incor- 
porated by reference. 
Animal models of anthracycline-induced cardiotoxicity 	 While the invention has been described in connection with (see, e.g., Herman and Ferrans, Semin. Oncol. 25:15-21,1998 	 specific embodiments thereof, it will be understood that it is 
and Heitman et al. Cancer Res. 58:195-197, 1998) are well- io capable of further modifications and this application is 
known in the art. Moreover, antibodies that block neuregulin 	 intended to cover any variations, uses, or adaptations of the 
binding to ErbB2 receptors, such as those described above, 	 invention following, in general, the principles of the invention 
are well-known. By inducing anthracycline/anti-ErbB2 anti- 	 and including such departures from the present disclosure 
body-dependent heart failure in known animal models for 	 come within known or customary practice within the art to 
anthracycline toxicity, one of skill in the art will readily be 15 which the invention pertains and may be applied to the essen- 
able to determine the neuregulin dosage regimen required to 	 tial features hereinbefore set forth, and follows in the scope of 
minimize or prevent such heart failure. 	 the appended claims. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 14 
<210> SEQ ID NO 1 
<211> LENGTH: 25 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 1 
tgtgctagtc aagagtccca accac 	 25 
<210> SEQ ID NO 2 
<211> LENGTH: 25 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 2 
ccttctctcg gtactaagta ttcag 	 25 
<210> SEQ ID NO 3 
<211> LENGTH: 25 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 3 
gcttaaagtg cttggctcgg gtgtc 	 25 
<210> SEQ ID NO 4 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 4 
tcctacacac tgacactttc tctt 	 24 
<210> SEQ ID NO 5 
<211> LENGTH: 26 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
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30 
-continued 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 5 
aattcaccca tcagagtgac gtttgg 	 26 
<210> SEQ ID NO 6 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 6 
tcctgcaggt agtctgggtg ctg 	 23 
<210> SEQ ID NO 7 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 7 
gctggctccg atgtatttga tggt 	 24 
<210> SEQ ID NO 8 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 8 
gttctctgcc gtaggtgtcc cttt 	 24 
<210> SEQ ID NO 9 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 9 
gcatcactgg ctgattctgg ag 	 22 
<210> SEQ ID NO 10 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<400> SEQUENCE: 10 
cacatgccgg ttatggtcag ca 	 22 
<210> SEQ ID NO 11 
<211> LENGTH: 754 
<212> TYPE: PRT 
<213> ORGANISM: Rattus norvegicus 
<400> SEQUENCE: 11 
Met Arg Arg Asp Pro Ala Pro Gly Phe Ser Met Leu Leu Phe Gly Val 
1 	 5 	 10 	 15 
Ser Leu Ala Cys Tyr Ser Pro Ser Leu Lys Ser Val Gin Asp Gin Ala 
20 	 25 	 30 
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-continued 
Tyr Lys Ala Pro Val Val Val Glu Gly Lys Val Gln Gly Leu Ala Pro 
35 	 40 	 45 
Ala Gly Gly Ser Ser Ser Asn Ser Thr Arg Glu Pro Pro Ala Ser Gly 
50 	 55 	 60 
Arg Val Ala Leu Val Lys Val Leu Asp Lys Trp Pro Leu Arg Ser Gly 
65 	 70 	 75 	 80 
Gly Leu Gln Arg Glu Gln Val Ile Ser Val Gly Ser Cys Ala Pro Leu 
85 	 90 	 95 
Glu Arg Asn Gln Arg Tyr Ile Phe Phe Leu Glu Pro Thr Glu Gln Pro 
100 	 105 	 110 
Leu Val Phe Lys Thr Ala Phe Ala Pro Val Asp Pro Asn Gly Lys Asn 
115 	 120 	 125 
Ile Lys Lys Glu Val Gly Lys Ile Leu Cys Thr Asp Cys Ala Thr Arg 
130 	 135 	 140 
Pro Lys Leu Lys Lys Met Lys Ser Gln Thr Gly Glu Val Gly Glu Lys 
145 	 150 	 155 	 160 
Gln Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gln Pro Ser Tyr 
165 	 170 	 175 
Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg 
180 	 185 	 190 
Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser Arg Leu Gln Phe Asn Lys 
195 	 200 	 205 
Val Lys Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile 
210 	 215 	 220 
Leu Gly Lys Asp Thr Val Arg Gly Arg Leu His Val Asn Ser Val Ser 
225 	 230 	 235 	 240 
Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr 
245 	 250 	 255 
Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly 
260 	 265 	 270 
Ile Asn Gln Leu Ser Cys Lys Cys Pro Val Gly Tyr Thr Gly Asp Arg 
275 	 280 	 285 
Cys Gln Gln Phe Ala Met Val Asn Phe Ser Lys His Leu Gly Phe Glu 
290 	 295 	 300 
Leu Lys Glu Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu Thr Ile Thr 
305 	 310 	 315 	 320 
Gly Ile Cys Val Ala Leu Leu Val Val Gly Ile Val Cys Val Val Ala 
325 	 330 	 335 
Tyr Cys Lys Thr Lys Lys Gln Arg Arg Gln Met His His His Leu Arg 
340 	 345 	 350 
Gln Asn Met Cys Pro Ala His Gln Asn Arg Ser Leu Ala Asn Gly Pro 
355 	 360 	 365 
Ser His Pro Arg Leu Asp Pro Glu Glu Ile Gln Met Ala Asp Tyr Ile 
370 	 375 	 380 
Ser Lys Asn Val Pro Ala Thr Asp His Val Ile Arg Arg Glu Ala Glu 
385 	 390 	 395 	 400 
Thr Thr Phe Ser Gly Ser His Ser Cys Ser Pro Ser His His Cys Ser 
405 	 410 	 415 
Thr Ala Thr Pro Thr Ser Ser His Arg His Glu Ser His Thr Trp Ser 
420 	 425 	 430 
Leu Glu Arg Ser Glu Ser Leu Thr Ser Asp Ser Gln Ser Gly Ile Met 
435 	 440 	 445 
Leu Ser Ser Val Gly Thr Ser Lys Cys Asn Ser Pro Ala Cys Val Glu 
450 	 455 	 460 
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34 
-continued 
Ala Arg Ala Arg Arg Ala Ala Ala Tyr Ser Gin Glu Glu Arg Arg Arg 
465 	 470 	 475 	 480 
Ala Ala Met Pro Pro Tyr His Asp Ser Ile Asp Ser Leu Arg Asp Ser 
485 	 490 	 495 
Pro His Ser Glu Arg Tyr Val Ser Ala Leu Thr Thr Pro Ala Arg Leu 
500 	 505 	 510 
Ser Pro Val Asp Phe His Tyr Ser Leu Ala Thr Gin Val Pro Thr Phe 
515 	 520 	 525 
Glu Ile Thr Ser Pro Asn Ser Ala His Ala Val Ser Leu Pro Pro Ala 
530 	 535 	 540 
Ala Pro Ile Ser Tyr Arg Leu Ala Glu Gin Gin Pro Leu Leu Gly His 
545 	 550 	 555 	 560 
Pro Ala Pro Pro Gly Pro Gly Pro Gly Pro Gly Ala Asp Met Gin Arg 
565 	 570 	 575 
Ser Tyr Asp Ser Tyr Tyr Tyr Pro Ala Ala Gly Pro Gly Pro Arg Arg 
580 	 585 	 590 
Gly Ala Cys Ala Leu Gly Gly Ser Leu Gly Ser Leu Pro Ala Ser Pro 
595 	 600 	 605 
Phe His Ile Pro Glu Asp Asp Glu Tyr Glu Thr Thr Gin Glu Cys Ala 
610 	 615 	 620 
Pro Pro Pro Pro Pro Arg Pro Arg Thr Arg Gly Ala Ser Arg Arg Thr 
625 	 630 	 635 	 640 
Ser Ala Gly Pro Arg Arg Trp Arg Arg Ser Arg Leu Asn Gly Leu Ala 
645 	 650 	 655 
Ala Gin Arg Ala Arg Ala Ala Arg Asp Ser Leu Ser Leu Ser Ser Gly 
660 	 665 	 670 
Ser Gly Cys Gly Ser Ala Ser Ala Ser Asp Asp Asp Ala Asp Asp Ala 
675 	 680 	 685 
Asp Gly Ala Leu Ala Ala Glu Ser Thr Pro Phe Leu Gly Leu Arg Ala 
690 	 695 	 700 
Ala His Asp Ala Leu Arg Ser Asp Ser Pro Pro Leu Cys Pro Ala Ala 
705 	 710 	 715 	 720 
Asp Ser Arg Thr Tyr Tyr Ser Leu Asp Ser His Ser Thr Arg Ala Ser 
725 	 730 	 735 
Ser Arg His Ser Arg Gly Pro Pro Thr Arg Ala Lys Gin Asp Ser Gly 
740 	 745 	 750 
Pro Leu 
<210> SEQ ID NO 12 
<211> LENGTH: 330 
<212> TYPE: PRT 
<213> ORGANISM: Rattus norvegicus 
<400> SEQUENCE: 12 
Met Arg Arg Asp Pro Ala Pro Gly Phe Ser Met Leu Leu Phe Gly Val 
1 	 5 	 10 	 15 
Ser Leu Ala Cys Tyr Ser Pro Ser Leu Lys Ser Val Gin Asp Gin Ala 
20 	 25 	 30 
Tyr Lys Ala Pro Val Val Val Glu Gly Lys Val Gin Gly Leu Ala Pro 
35 	 40 	 45 
Ala Gly Gly Ser Ser Ser Asn Ser Thr Arg Glu Pro Pro Ala Ser Gly 
50 	 55 	 60 
Arg Val Ala Leu Val Lys Val Leu Asp Lys Trp Pro Leu Arg Ser Gly 
65 	 70 	 75 	 80 
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-continued 
Gly Leu Gin Arg Glu Gin Val Ile Ser Val Gly Ser Cys Ala Pro Leu 
85 	 90 	 95 
Glu Arg Asn Gin Arg Tyr Ile Phe Phe Leu Glu Pro Thr Glu Gin Pro 
100 	 105 	 110 
Leu Val Phe Lys Thr Ala Phe Ala Pro Val Asp Pro Asn Gly Lys Asn 
115 	 120 	 125 
Ile Lys Lys Glu Val Gly Lys Ile Leu Cys Thr Asp Cys Ala Thr Arg 
130 	 135 	 140 
Pro Lys Leu Lys Lys Met Lys Ser Gin Thr Gly Glu Val Gly Glu Lys 
145 	 150 	 155 	 160 
Gin Ser Leu Lys Cys Glu Ala Ala Ala Gly Asn Pro Gin Pro Ser Tyr 
165 	 170 	 175 
Arg Trp Phe Lys Asp Gly Lys Glu Leu Asn Arg Ser Arg Asp Ile Arg 
180 	 185 	 190 
Ile Lys Tyr Gly Asn Gly Arg Lys Asn Ser Arg Leu Gin Phe Asn Lys 
195 	 200 	 205 
Val Lys Val Glu Asp Ala Gly Glu Tyr Val Cys Glu Ala Glu Asn Ile 
210 	 215 	 220 
Leu Gly Lys Asp Thr Val Arg Gly Arg Leu His Val Asn Ser Val Ser 
225 	 230 	 235 	 240 
Thr Thr Leu Ser Ser Trp Ser Gly His Ala Arg Lys Cys Asn Glu Thr 
245 	 250 	 255 
Ala Lys Ser Tyr Cys Val Asn Gly Gly Val Cys Tyr Tyr Ile Glu Gly 
260 	 265 	 270 
Ile Asn Gin Leu Ser Cys Lys Cys Pro Asn Gly Phe Phe Gly Gin Arg 
275 	 280 	 285 
Cys Leu Glu Lys Leu Pro Leu Arg Leu Tyr Met Pro Asp Pro Lys Gin 
290 	 295 	 300 
Ser Val Leu Trp Asp Thr Pro Gly Thr Gly Val Ser Ser Ser Gin Trp 
305 	 310 	 315 	 320 
Ser Thr Ser Pro Ser Thr Leu Asp Leu Asn 
325 	 330 
<210> SEQ ID NO 13 
<211> LENGTH: 182 
<212> TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 13 
Arg Gly Glu Gly Ile Ser Phe Pro Ser Lys Leu Gin Gly His Cys Gly 
1 	 5 	 10 	 15 
Ser Val Glu Arg Gly Asn Arg Trp Val Thr Ala Gly Glu Pro Gin Pro 
20 	 25 	 30 
Ala Leu Ala His Ala Ser Pro Pro Phe Ile Pro Ser Leu Thr Arg Lys 
35 	 40 	 45 
Asn Ser Arg Leu Gin Phe Asn Lys Val Lys Val Glu Asp Ala Gly Glu 
50 	 55 	 60 
Tyr Val Cys Glu Ala Glu Asn Ile Leu Gly Lys Asp Thr Val Arg Gly 
65 	 70 	 75 	 80 
Arg Leu Tyr Val Asn Ser Val Ser Thr Thr Leu Ser Ser Trp Ser Gly 
85 	 90 	 95 
His Ala Arg Lys Cys Asn Glu Thr Ala Lys Ser Tyr Cys Val Asn Gly 
100 	 105 	 110 
Gly Val Cys Tyr Tyr Ile Glu Gly Ile Asn Gin Leu Ser Cys Lys Cys 
115 	 120 	 125 
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-continued 
Pro Asn Gly Phe Phe Gly Gln Arg Cys Leu Glu Lys Leu Pro Leu Arg 
130 	 135 	 140 
Leu Tyr Met Pro Asp Pro Lys Gln Ser Val Leu Trp Asp Thr Pro Gly 
145 	 150 	 155 	 160 
Thr Gly Val Ser Ser Ser Gln Trp Ser Thr Ser Pro Lys Pro Arg Ser 
165 	 170 	 175 
Cys Thr Arg Arg Gly Ser 
180 
<210> SEQ ID NO 14 
<211> LENGTH: 3020 
<212> TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<400> SEQUENCE: 14 
cctccaggtc ctggcgcaca gggtgggagc gctgcgctgc gccgcgctgc gcatcgcggc 	 60 
ccgcttgccg cctgccccct gccctagctg ggccacctcc ccgggctgcc ggtggagggc 	 120 
taagaggcgc taacgttacg ctgtttccgg ttttccagcg ggctctgttt cccctcccaa 	 180 
ggcggcggcg gctgagcggc ggagcccccc aaatggcctg gccagatgcg gcaggtttgc 	 240 
tgctcagcgc tgccgccgcc gccactggag aagggtcggt gcagcagcta cagcgacagc 	 300 
agcagcagca gcagcgagag gagcagcagc agcagcagca gcagcagcga gagcggcagc 	 360 
agcagcagga gcagcagcaa caacagcagc atctctcgtc ccgctgcgcc cccagagccg 	 420 
cggccgcagc aacagccgca gccccgcagc cccgcagccc ggagagccgc cgcccgttcg 	 480 
cgagccgcag ccgccggcgg catgaggcgc gacccggccc ccggcttctc catgctgctc 	 540 
ttcggtgtgt cgctcgcctg ctactcgccc agcctcaagt cagtgcagga ccaggcgtac 	 600 
aaggcacccg tggtggtgga gggcaaggta caggggctgg tcccagccgg cggctccagc 	 660 
tccaacagca cccgagagcc gcccgcctcg ggtcgggtgg cgttggtaaa ggtgctggac 	 720 
aagtggccgc tccggagcgg ggggctgcag cgcgagcagg tgatcagcgt gggctcctgt 	 780 
gtgccgctcg aaaggaacca gcgctacatc tttttcctgg agcccacgga acagccctta 	 840 
gtctttaaga cggcctttgc ccccctcgat accaacggca aaaatctcaa gaaagaggtg 	 900 
ggcaagatcc tgtgcactga ctgcgccacc cggcccaagt tgaagaagat gaagagccag 	 960 
acgggacagg tgggtgagaa gcaatcgctg aagtgtgagg cagcagccgg taatccccag 	 1020 
ccttcctacc gttggttcaa ggatggcaag gagctcaacc gcagccgaga cattcgcatc 	 1080 
aaatatggca acggcagaaa gaactcacga ctacagttca acaaggtgaa ggtggaggac 	 1140 
gctggggagt atgtctgcga ggccgagaac atcctgggga aggacaccgt ccggggccgg 	 1200 
ctttacgtca acagcgtgag caccaccctg tcatcctggt cggggcacgc ccggaagtgc 	 1260 
aacgagacag ccaagtccta ttgcgtcaat ggaggcgtct gctactacat cgagggcatc 	 1320 
aaccagctct cctgcaaatg tccaaatgga ttcttcggac agagatgttt ggagaaactg 	 1380 
cctttgcgat tgtacatgcc agatcctaag caaaaagccg aggagctgta ccagaagagg 	 1440 
gtcctgacca tcacgggcat ctgcgtggct ctgctggtcg tgggcatcgt ctgtgtggtg 	 1500 
gcctactgca agaccaaaaa acagcggaag cagatgcaca accacctccg gcagaacatg 	 1560 
tgcccggccc atcagaaccg gagcttggcc aatgggccca gccacccccg gctggaccca 	 1620 
gaggagatcc agatggcaga ttatatttcc aagaacgtgc cagccacaga ccatgtcatc 	 1680 
aggagagaaa ctgagaccac cttctctggg agccactcct gttctccttc tcaccactgc 	 1740 
tccacagcca cacccacctc cagccacaga cacgagagcc acacgtggag cctggaacgt 	 1800 
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40 
-continued 
tctgagagcc tgacttctga ctcccagtcg gggatcatgc tatcatcagt gggtaccagc 	 1860 
aaatgcaaca gcccagcatg tgtggaggcc cgggcaaggc gggcagcagc ctacaacctg 	 1920 
gaggagcggc gcagggccac cgcgccaccc tatcacgatt ccgtggactc ccttcgcgac 	 1980 
tccccacaca gcgagaggta cgtgtcggcc ctgaccacgc ccgcgcgcct ctcgcccgtg 	 2040 
gacttccact actcgctggc cacgcaggtg ccaactttcg agatcacgtc ccccaactcg 	 2100 
gcgcacgccg tgtcgctgcc gccggcggcg cccatcagtt accgcctggc cgagcagcag 	 2160 
ccgttactgc ggcacccggc gccccccggc ccgggacccg gacccgggcc cgggcccggg 	 2220 
cccggcgcag acatgcagcg cagctatgac agctactatt accccgcggc ggggcccgga 	 2280 
ccgcggcgcg ggacctgcgc gctcggcggc agcctgggca gcctgcctgc cagccccttc 	 2340 
cgcatccccg aggacgacga gtacgagacc acgcaggagt gcgcgccccc gccgccgccg 	 2400 
cggccgcgcg cgcgcggtgc gtcccgcagg acgtcggcgg ggccccggcg ctggcgccgc 	 2460 
tcgcgcctca acgggctggc ggcgcagcgc gcacgggcgg cgagggactc gctgtcgctg 2520 
agcagcggct cgggcggcgg ctcagcctcg gcgtcggacg acgacgcgga cgacgcggac 2580 
ggggcgctgg cggccgagag cacacctttc ctgggcctgc gtggggcgca cgacgcgctg 2640 
cgctcggact tgccgccact gtgcccggcg gccgacagca ggacttacta ctcactggac 2700 
agccacagca cgcgggccag cagcagacac agccgcgggc cgcccccgcg ggccaagcag 2760 
gactcggcgc cactctaggg ccccgccgcg cgcccctccg ccccgcccgc cccactatct 	 2820 
ttaaggagac cagagaccgc ctactggaga gaaaggagga aaaaagaaat aaaaatattt 	 2880 
ttattttcta taaaaggaaa aaagtataac aaaatgtttt attttcattt tagcaaaaat 	 2940 
tgtcttataa tactagctaa cggcaaaggc gtttttatag ggaaactatt tatatgtaac 	 3000 
atcctgattt acagcttcgg 	 3020 
What is claimed is: tolic dysfunction; coronary bypass surgery; starvation; an 
1. A method for treating or preventing congestive heart eating disorder; or a genetic defect. 
failure in a mammal, said method comprising administering a 40 11. The method of claim 10, wherein said mammal has 
polypeptide comprising an epidermal growth factor-like undergone a myocardial infarction. 
(ECG-like) domain to said mammal, wherein said EGF-like 12. The method of claim 10, wherein said cardiotoxic 
domain is encoded by a neuregulin gene, wherein said admin- compound is an anthracycline, alcohol, or cocaine. 
istering is in an amount effective to treat or prevent heart 13. The method of claim 12, wherein said anthracycline is 
failure in said mammal. 	 45 doxorubicin or daunomycin. 
2. The method of claim 1, wherein said neuregulin gene is 14. The method of claim 12, wherein an anti-ErbB2 or 
the NRG-1 gene. anti-HER2 antibody is administered to said mammal before, 
3. The method of claim 2, wherein said polypeptide is during, or after anthracycline administration. 
encoded by the NRG-1 gene. 15. The method of claim 12, wherein said cardiotoxic 
4. The method of claim 3, wherein said polypeptide is 50 compound is an anti-ErbB2 or anti-HER2 antibody. 
recombinant human GGF2. 16. The method of claim 14 or 15, wherein said anti-ErbB2 
5. The method of claim 1, wherein said neuregulin gene is or anti-HER2 antibody is HERCEPTINO. 
the NRG-2 gene. 17. The method of claim 12, wherein said polypeptide is 
6. The method of claim 5, wherein said polypeptide is administered prior to exposureto said cardiotoxic compound. 
encoded by the NRG-2 gene. 	 55 18. The method of claim 12, wherein said polypeptide is 
7. The method of claim 1, wherein said neuregulin gene is administered during exposure to said cardiotoxic compound. 
the NRG-3 gene. 19. The method of claim 12, wherein said polypeptide is 
8. The method of claim 7, wherein said polypeptide is administered after exposure to said cardiotoxic compound. 
encoded by the NRG-3 gene. 20. The method of claim 1, wherein said polypeptide is 
9. The method of claim 1, wherein said mammal is a 6o administered prior to the diagnosis of congestive heart failure 
human. in said mammal. 
10. The method of claim 1, wherein said congestive heart 21. The method of claim 1, wherein said polypeptide is 
failure results from hypertension; ischemic heart disease; administered after the diagnosis of congestive heart failure in 
exposure to a cardiotoxic compound; myocarditis; thyroid said mammal. 
disease; viral infection; gingivitis; drug abuse; alcohol abuse; 	 65 22. The method of claim 1, wherein said polypeptide is 
periocarditis; atherosclerosis; vascular disease; hypertrophic administered to a mammal that has undergone compensatory 
cardiomyopathy; myocardial infarction; left ventricular sys- cardiac hypertrophy. 
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23. The method of claim 1, wherein administration of said 	 26. The method of claim 1, wherein said polypeptide is 
polypeptide maintains left ventricular hypertrophy. 	 administeredby administering an expression vector encoding 
24. The method of claim 1, wherein said method prevents 	 said polypeptide to said mammal. 
progression of myocardial thinning. 
25. The method of claim 1, wherein administration of said 5 
polypeptide inhibits cardiomyocyte apoptosis. 
